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Background: Antipsychotic drugs are primary medication for patients suffering 
schizophrenia. Although these drugs are effective for the treatment of positive and 
negative symptoms, the chronic administration of these drugs is associated with 
cognitive deficits, decreased volume of grey matter, and reduced cortical thickness 
in schizophrenic patients. Sodium butyrate, one of histone deacetylase 2 (HDAC2) 
inhibitors, has been shown to promote synaptogenesis in neurons and reinstate 
cognitive function in animal models of neurodegeneration diseases. This study 
aimed to examine the side effect and mechanism of olanzapine, one of the most 
commonly prescribed antipsychotic drugs, on synaptogenesis in neurons, and the 
possible neuroprotective effect of sodium butyrate.  
Methods: The SH-SY5Y neuronal cell or primary cortical neurons were treated 
with olanzapine, butyrate, or combination of olanzapine and butyrate followed by 
the examination of neurite morphology. Neurite morphology, including neurite 
length and spine density, was analysed by using the IncucyteZoom system and the 
confocal microscopy. The production of reactive oxygen species (ROS) was 
determined with flow cytometry and fluorescence microscopy. The western blot 
was used to determine the change of sirtuin 1 (Sirt1), p65, p50, HDAC2, and  
brain-derived neurotrophic factor (BDNF) protein expression in SH-SY5Y cells. 
RT-PCR technique was used to determine the mRNA level of BDNF,  
microtubule-associated protein 2 (MAP2), synaptophysin, and postsynaptic density 
protein 95 (PSD95) in primary cortical neurons. Moreover, the enzyme activity of 
recombinant and SH-SY5Y cells-derived HDAC2 was investigated by using 
deacetylase activity assay kits. 
Results: The treatment of olanzapine significantly decreased neurite outgrowth and 
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lowered dendritic spine density in SH-SY5Y cells and cortical neurons, 
respectively. Furthermore, olanzapine led to oxidative stress and decreased Sirt1 
expression, thereby activating the NF-κB signaling pathway. Olanzapine increased 
the protein level of HDAC2 and decreased mRNA and protein levels of BDNF. 
Furthermore, overexpression of p65, the subunit of NF-κB, resulted in the 
upregulation of HDAC2 protein level in SH-SY5Y cells, suggesting that activation 
of NF-κB may contribute to HDAC2 upregulation induced by olanzapine. Sodium 
butyrate rescued neuronal damages induced by olanzapine. Despite sodium 
butyrate did not affect the oxidative stress/Sirt1-NF-κB-HDAC2 pathway, it 
blocked the deacetylase activity of HDAC2 significantly and restored the BDNF 
expression.  
Conclusion: This study suggests that olanzapine can induce neurite lesions. 
Furthermore, it unravels the underlying mechanism of olanzapine-induced neurite 
lesions involving in the oxidative stress/Sirt -NF-κB -HDAC2 -BDNF pathway. 
Also, this study indicates that sodium butyrate, an HDAC2 enzyme inhibitor, has 
the neuroprotective effect on the neuronal lesion induced by olanzapine. Since 
butyrate has been safely used in the clinical trial of anti-inflammation, my findings 
suggest that sodium butyrate can be used to prevent the abnormal synaptogenesis 
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1. Overview of schizophrenia 
Schizophrenia is a heritable psychiatric disorder and affects approximately 1% 
of the population worldwide. Symptoms of schizophrenia are manifested late in 
childhood or early in adulthood, and are classified into three groups: positive 
symptoms, like hallucination, delusion, and other thought disorders, negative 
symptoms, such as social withdrawal, lack of motivation and blunted affect, and 
cognitive symptoms, such as memory defects and attentional deficits (Dawe et 
al., 2009, Ghoshal et al., 2016, Lewis and Lieberman, 2000). The etiology and 
pathophysiology of schizophrenia are still not very clear. However, the 
pathological feature of schizophrenic patients is shown as losing grey matter and 
less synaptic structures on neurons (Glausier and Lewis, 2013). Additionally, the 
abnormality in gene and environmental factors are considered as contributors to 
schizophrenia. It has been confirmed that schizophrenia is associated with the 
mutation of multiple genes by molecular genetic studies, such as genome-wide 
association study (GWAS) arrays (Owen et al., 2005, Ripke et al., 2014). Among 
these candidate genes, the neuregulin 1 (NRG1), dysbindin-1 (DTNBP1), v-akt 
murine thymoma viral oncogene homolog (Akt), and disrupted in schizophrenia 
1 (DISC1) are received attention in recent years because of their significance in 
neurotransmission, neuroplasticity, and neurodevelopment (Bellon, 2007).  
 
2. Antipsychotics treatment for schizophrenia 
The medication for schizophrenia is divided into two groups as first-generation 
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antipsychotics (FGA) and second-generation antipsychotics (SGA). The FGA, such 
as chlorpromazine and haloperidol, acts as the dopamine D2 receptor antagonist to 
reduce positive symptoms (Luft and Taylor, 2006). However, the long-term 
medication of FGAs can result in side effects as extrapyramidal side effects (EPSEs) 
and hyperprolactinemia (Lally and MacCabe, 2015). To minimize these side effects, 
the SGA, such as clozapine, olanzapine, and risperidone, is developed and is 
considered as prominent antagonists for the serotonin 5-HT2A receptor combined 
with the dopamine D2 receptor (Hill et al., 2010, Thomas and Lewis, 1998). SGAs 
have more efficacy on negative symptoms compared with FGAs, whereas it is 
reported that SGAs are associated with weight gain and cardiometabolic adverse 
effects in schizophrenic patients (Leucht et al., 2009). Olanzapine, a kind of 
thienobenzodiazepine derivatives, shows effective therapeutic effects on psychotic 
symptoms in schizophrenic patients (Beasley et al., 1996). It is confirmed that 
olanzapine can bind with various receptors as dopamine receptors (1~5), serotonin 
receptors (5HT2A/5HT2C/5HT3/5HT6), muscarinic receptors, α1-adrenergic 
receptors and histamine H1 receptors (Bymaster et al., 1998, Bymaster et al., 1997, 
Roth et al., 1994). It demonstrates that olanzapine has a higher binding affinity with 
the serotonin 5-HT2A receptor and the dopamine D2 receptor with occupancy as 70% 
and 30%, respectively (Kusumi et al., 2000, Huang et al., 2006). 
 
3. Cognition and synaptogenesis 
Cognitive function is defined as the ability to get attention, learning and memory, 
speed of information processing, psychomotor ability, and executive functions 
(Lawlor, 2002, Moriarty et al., 2011). Cognitive deficits are found in many mental 
diseases, including schizophrenia, dementia, and other psychotic disorders, which 
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is associated with the neuropathological process, such as loss of synaptic elements 
and alteration of cerebral white matter (Dwork et al., 2007). The neuron consists of 
a cell body (soma) and neurites, such as axons and dendrites (Figure 1-1) 
(Rochefort and Konnerth, 2012). Synapses are junctions between neurons for 
neuronal communication. Dendrites are tree-like structures and are extended from 
the soma. Dendritic spines are protrusions in the dendrite for further synaptic 
connections and excitatory inputs (Lodish et al., 2008). Dendritic spines are usually 
classified as filopodia-liked spines, stubby spines, thin spines, and mushroom 
spines. Mushroom spines, as memory spines, can anchor many neurotransmitter 
receptors and can exist for few months; whereas thin spines, as learning spines, 
contain fewer neurotransmitter receptors and persist for few days (Bourne and 
Harris, 2007, Dunaevsky et al., 1999, Ziv and Smith, 1996, Matsuzaki et al., 2001). 
The stubby and filopodia-liked spines are dynamic and are considered as immature 
spines due to lacking of postsynaptic density proteins (Berry and Nedivi, 2017). 
The decreased neurite outgrowth and spine density are associated with cognitive 
Figure 1-1 The structure of the neuron. The basic component of a neuron, including dendrites, 
a axon, the myelin sheath, the cell body, the nucleus, nodes of Ranvier. Besides, the morphology 




impairment (Huang and Song, 2019). The brain-derived neurotrophic factor 
(BDNF), which is an important regulator for neuronal development, synaptic 
transmission, and synaptic plasticity, can promote the formation and maintenance 
of memory (Garraway and Huie, 2016). A study confirmed that the increased 
BDNF in the medium led to stimulation of its receptor tyrosine kinase B (TrkB) 
and downstream signaling pathway in rat hippocampal neurons, which promoted 
synaptogenesis (Ji et al., 2010). Also, BDNF administration facilitated 
neurotransmission and synaptogenesis in pyramidal neurons of rodents (Tyler and 
Pozzo-Miller, 2001, Tyler and Pozzo-Miller, 2003). Moreover, the administration 
of BDNF-mimetic treatment restored the synaptic plasticity and cognition in mouse 
models of Down’s Syndrome (Parrini et al., 2017). Postsynaptic density protein 95 
(PSD95) is a scaffolding protein involved in synaptic development and plasticity 
(Funke et al., 2005). Synaptophysin is a membrane protein of pre-synapse and plays 
an important role in synaptogenesis (Gudi et al., 2017). Microtubule-associated 
protein 2 (MAP2) is critical for the improvement of neuromorphogenesis, as the 
origination of neurites (Dehmelt and Halpain, 2004). Therefore, alteration of the 
neurotrophic factor, as BDNF, and synaptic proteins, as PSD95, synaptophysin, and 
MAP2, contributes to neuronal lesions, synapse loss, and cognitive impairments. 
 
4. Chronic treatment of antipsychotic drugs leads to cognitive deficits and 
neuronal lesions  
Although antipsychotic drugs show efficacy in the treatment of positive and 
negative symptoms, the cognitive deficit has been found in schizophrenic patients 
and animal models with chronic administration. For example, the lifelong 
medication of antipsychotics was associated with poor cognitive performance and 
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decline in verbal learning and memory, which was determined in a  
9-year follow-up study (Husa et al., 2014). Also, a significant loss of cortical grey 
matter was found in schizophrenic patients with the long-term medication of 
antipsychotics in a meta-analysis based on 18 studies (Vita et al., 2015). Besides, 
the chronic administration of antipsychotic drugs impaired abilities of short-term 
recognition memory and spatial learning in rats (Schröder et al., 2005, Rosengarten 
and Quartermain, 2002). Therefore, the cognitive impairment, including the loss in 
attention, impairments in executive function, and poor working memory, may be 
caused by chronic administration of antipsychotics in schizophrenia. Furthermore, 
the treatment of antipsychotics, as haloperidol and clozapine, resulted in shorter 
neurite outgrowth and decreased density of synaptic spines in neuroblastoma cells 
and primary neurons (Hu et al., 2018, Ibi et al., 2017).  
 
Clinically, clozapine and olanzapine are the most commonly prescribed 
medications (Ashcroft et al., 2002, Winckel and Siskind, 2017). Clozapine is 
available only for oral administration (Asenjo‐Lobos et al., 2018). It is prescribed 
for the schizophrenic patients whose symptoms cannot be controlled with standard 
antipsychotic drugs; however, a safe therapeutic dosage range for clozapine has not 
been established due to variation in individual responses. Clozapine is a restricted 
drug by the US Food and Drug Administration (FDA) that requires periodic 
hematological monitoring (Stark and Scott, 2012), as it can result in severe adverse 
effects, such as hematological disorders like agranulocytosis (decline in the number 
of white blood cells, particularly in neutrophils) (Asenjo‐Lobos et al., 2018). In a 
review published in Lancet, the number of participants assigned to the treatment 
and clinical trials of olanzapine is the highest compared with that of other 
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antipsychotics (Huhn et al., 2019). There are various types of olanzapine 
interventions, such as oral administration and intramuscular injection. Clinically, 
oral administration of olanzapine is used for schizophrenia, acute treatment of 
manic or mixed episodes associated with bipolar I disorder, and maintenance 
treatment of bipolar I disorder. The injectable formulation is approved to treat acute 
agitation associated with schizophrenia and bipolar I mania. The previous research 
has reported that clozapine administration impaired synaptogenesis and cognition 
in rodents (Ibi et al., 2017). In this thesis, the direct effects of olanzapine on the 
synaptogenesis will be examined in neurons. 
 
5.  Oxidative stress induces cognition deficits and neuronal lesions 
The oxidative stress, which can induce cell damages, is defined as a higher 
proportion of pro-oxidants compared with antioxidants (Sies, 1997). The reactive 
oxygen species (ROS) (pro-oxidants) includes superoxide anion radicals, hydrogen 
peroxide, singlet oxygen, ozone, hydroxyl radicals, and organic peroxides. 
Moreover, biological antioxidants (glutathione, α-tocopherol, carotenoids, and 
ascorbic acid) and antioxidant enzymes (peroxide dismutase, catalases, and 
glutathione peroxidase) can react and detoxify the ROS  
(Nathan and Cunningham-Bussel, 2013, Klein and Ackerman, 2003). Mitochondria 
is the primary source of ROS, since the superoxide dismutase inside mitochondria 
can generate the superoxide and hydrogen peroxide (Loschen et al., 1974, Forman 
and Kennedy, 1974, Munro and Treberg, 2017). The brain consumes 20% oxygen, 
which is the primary precursor of ROS, to satisfy the high rate of metabolism (Rink 
and Khanna, 2011). Besides, the metabolism of the high proportion of oxidized 
molecules, such as polyunsaturated fatty acid and oxidized neurotransmitters 
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(dopamine, epinephrine, and norepinephrine), generates a large quantity of ROS in 
the brain (Mahadik and Mukherjee, 1996, Halliwell, 2001). Also, the lower level 
of antioxidant enzymes in the brain indicates that the oxidative stress easily 
occurred and the brain is vulnerable to the ROS (Bošković et al., 2011).  
 
Currently available studies prove that decreased antioxidant defense and higher 
ROS level is shown in schizophrenic patients with deficits in executive function 
(Bošković et al., 2011, Prabakaran et al., 2004, Gonzalez-Liencres et al., 2014), 
which indicates that the oxidative stress is involved in the pathology of 
schizophrenia and contribute to cognition dysfunction in schizophrenic patients 
(Zhang et al., 2015). In rat models of chronic ischemia, the memory and learning 
capacity was impaired with the higher ROS level in the hippocampus and frontal 
cortex, however, the administration of ROS scavengers relived that damage (Li and 
Zhang, 2015). The rats exposed to ozone (under oxidative stress state) showed  
long-term memory deficits and decreased spine density in the hippocampus  
(Avila-Costa et al., 1999). Treatment of hydrogen peroxides induced lower cell 
viability and decreased neurite outgrowth of SH-SY5Y neuroblastoma cells in a 
time-dependent manner (Ashabi et al., 2013). Moreover, oxidative stress caused by 
a high saturated fat diet resulted in decreased BDNF expression and induced 
cognitive impairments (Wu et al., 2004). Anti-psychotics such as clozapine has 
been found to induce oxidative stress in neutrophils of schizophrenic patients 
(Fehsel et al., 2005), as well as rat models (Polydoro et al., 2004). Olanzapine also 
induces oxidative stress in rats (Todorović et al., 2016); however, whether 




6. Sirt1 is involved in neurogenesis and mental diseases 
Mammalian sirtuins (Sirt1~Sirt7) are nicotinamide adenine dinucleotide (NAD+) 
dependent deacetylases with high levels of homology to gene silent information 
regulator 2 in Saccharomyces cerevisiae (Nogueiras et al., 2012). It is known that 
sirtuins regulate lifespan, gene silencing, DNA repair, and ribosomal DNA 
recombination (Wood et al., 2004, Kanfi et al., 2012). Sirtuins belong to class III 
histone deacetylases (HDACs), but they do not have zinc atom at catalytic sites, 
which indicates that some sirtuins may not have deacetylase activity (Dokmanovic 
et al., 2007). Sirt1, which is one of the sirtuin family and exhibits deacetylase 
activity, can improve neurodevelopment and ameliorate neurodegenerative 
disorders (Herskovits and Guarente, 2014). It has been confirmed that Sirt1 
activators (resveratrol and NAD) enhanced the neurite outgrowth in PC12 
(pheochromocytoma) cells, while treatment with Sirt1 inhibitors (nicotinamide and 
splitomicin) or Sirt1 siRNA impaired the neurite outgrowth (Sugino et al., 2010). 
Another study demonstrated that the inhibition of Sirt1 impaired the differentiation 
of neural precursor cells (NPCs) into neurons; however, the treatment of Sirt1 
activators enhanced the neuronal differentiation (Hisahara et al., 2008). In primary 
hippocampal neurons, Sirt1 siRNA resulted in impairments in axon elongation and 
branching, but the treatment of Sirt1 vector and activator induced axonogenesis (Li 
et al., 2013). Sirt1 inhibition blocked the axon generation in dorsal root ganglion 
sensory neurons; besides, Sirt1 overexpression counteracted the impairment in 
axon length induced by microRNA-138 (Liu et al., 2013). In Sirt1 knockout mice, 
the decreased dendritic branching and arborization were along with cognitive 
function defects (Michán et al., 2010). Another study confirmed that the impaired 
synaptic plasticity and decreased expression of BDNF were shown in Sirt1 
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knockout mice with cognitive deficits (Gao et al., 2010). These findings indicate 
that Sirt1 plays a vital role in the promotion of neurogenesis. 
 
Treatment with resveratrol (Sirt1 activator) or overexpression of Sirt1 ameliorated 
the primary neuron death and degeneration in mouse models of dementia (Kim et 
al., 2007). Furthermore, it suggested that the Sirt1 deficiency induced the 
acetylation of Tau protein, which blocked its ubiquitination and degradation (Min 
et al., 2010). Also, Min’s team found that Sirt1 deficiency resulted in the 
accumulation of phosphorylated Tau, which induced tau-mediated 
neurodegeneration. Knockdown of Sirt1 exacerbated the neurodegeneration in 
mouse models of Huntington’s disease; however, the overexpression of Sirt1 
ameliorated that effect and increased BDNF expression (Jeong et al., 2012, Jiang et 
al., 2011). It is confirmed that the Sirt1 gene is involved in the pathogenesis of 
schizophrenia (Kishi et al., 2011). Treatment of resveratrol increased the protein 
level of Sirt1 and BDNF and alleviated oxidative stress in the hippocampus of rat 
models of schizophrenia induced by MK801(Niu et al., 2020). These findings 
above imply that Sirt1 plays a crucial role in the pathogenesis of mental diseases. 
 
7. Interaction between oxidative stress and Sirt1 
Previous researches suggest that there is a crosstalk between Sirt1 and oxidative 
stress, evidenced by the Sirt1 was upregulated in response to the oxidative stress, 
whereas the moderate overexpression of Sirt1 induced the antioxidant system to 
ameliorate the oxidative stress (Alcendor et al., 2007). For example, Sirt1 
deacetylated the FOXO transcription factor, which stimulated the production of 
antioxidant enzymes (superoxide dismutase and catalase) and antioxidants 
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(selenoprotein P and ceruloplasmin) (Klotz et al., 2015, Kobayashi et al., 2005). 
Also, Sirt1 can bind and deacetylate the NF-κB to regulate the production of 
antioxidants and pro-oxidants (Yeung et al., 2004). Another transcription  
factor — Nrf2 is deacetylated by Sirt1, which induces its translocation from the 
nucleus into the cytoplasm and terminates the antioxidant defense (Kawai et al., 
2011). Moreover, the Sirt1 shows deacetylase activity at promoters of uncoupling 
proteins (UCP2 and UCR3) and suppresses the transcription of UCPs to attenuate 
the accumulation of ROS in mitochondria (Bordone et al., 2006, Amat et al., 2007, 
Brand and Esteves, 2005). Besides, oxidative stress induces the activation of Jun 
N-terminal kinase 1 (JNK1), which results in phosphorylation of Sirt1 at Ser27, 
Ser47 and Thr530 residues, and improves the deacetylase activity of Sirt1 (Nasrin 
et al., 2009, Kamata et al., 2005). However, persistent stimulation of JNK1 induced 
by insulin and glucose results in degradation of Sirt1 (Gao et al., 2011).  
MicroRNA-34a stimulated by oxidative stress can bind with the 3’UTR region of 
Sirt1 mRNA and inhibit the transcription of Sirt1 (Baker et al., 2016, Yamakuchi 
et al., 2008). Treatment of hydrogen peroxide led to the carbonylation on cysteine 
residues of Sirt1, which reduced the protein expression and deacetylase activity of 
Sirt1 in human lung epithelial cells (Caito et al., 2010).  
 
8. Activation of the NF-κB signaling pathway is involved in neuronal lesions 
Nuclear factor kappa B (NF-κB) is a homodimeric or heterodimeric protein 
complex, which can act as a transcription factor to regulate cell proliferation, 
differentiation, apoptosis, inflammation response and other biological processes 
(Donadelli et al., 2000). NF-κB family members, including NF-κB1 (p50/p105), 
RelA (p65), NF-κB2 (p52/p100), c-Rel, and RelB, share the Rel Homology Domain 
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(RHD) in their sequence (Serasanambati and Chilakapati, 2016). In resting cells, 
the NF-κB dimer is sequestered with NF-κB inhibitors (IκB), including IkBα, IkBβ, 
IkBɛ, Bcl-3, and precursors of Rel-proteins, at RHD to remain an inactive form in 
the cytoplasm (Strickland and Ghosh, 2006). When the NF-κB signaling pathway 
is activated, the specific IκB kinases (IKK) is activated to phosphorylate the IκB, 
which triggers ubiquitination and degradation of IκB. Then the free NF-κB 
translocates into the nucleus, which leads to binding with DNA sequences and 
regulation of the transcription (Salminen et al., 2008a). In response to different 
stimuli, the NF-κB signaling pathway is divided into the canonical pathway and the 
alternative pathway (Figure 1-2) (Dolcet et al., 2005). The canonical pathway is 
predominately stimulated by TNF-α, IL-1, and lipopolysaccharide, then the IKK 
phosphorylates the IκB, which undergoes ubiquitin-dependent degradation by the 
proteasome. The free NF-κB dimer, which consists of p50 with either RelA or  
Figure 1-2 The schematic diagram of the activation of the NF-κB signaling pathway. Two 
pathways can activate the translocation of NF-κB dimer into the nucleus, as canonical and 
alternative pathways. For canonical pathway, the IKK complex phosphorylates IκB and triggers its 
degradation by proteasomes. The RelA/p50 complex is free and translocates into the nucleus, 
resulting in the regulation of target genes. For alternative pathway, p100 is phosphorylated and 
proteolyzed into the p52 mature form before the NF-κB dimer (P52/RelB) translocates into the 
nucleus, which regulates the transcription of target genes. 
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c-Rel, translocates into the nucleus and acts as the transcription factor. The 
alternative pathway is predominately triggered via stimulation of CD40, 
lymphotoxin B, and BAFF (B cell activating factor). When the alternative pathway 
is stimulated, the NF-κB inducing kinase (NIK) is activated to phosphorylate the 
IKK complex. Then the p100, a precursor of Rel-protein, is phosphorylated by the 
IKK complex and proteolyzed to generate the mature form (p52), which results in 
the liberation of the RelB-p52 complex to regulate the gene transcription 
(Serasanambati and Chilakapati, 2016, Dolcet et al., 2005). 
The activation of the NF-κB signaling pathway is involved in neuronal lesions. For 
example, activation of the NF-κB signaling pathway induced by hydrogen peroxide 
led to apoptosis in SH-SY5Y neuroblastoma cells (Larouche et al., 2008, Mendell 
et al., 2016), which suggest that oxidative stress may activate the NF-κB signaling 
pathway and induce neuronal lesions. In addition, it is demonstrated that the Sirt1 
deacetylated p65, a subunit of NF-κB, and blocked its translocation into the nucleus 
in HEK 293T cells (Yeung et al., 2004), which suggest that Sirt1 can inhibit the 
NF-κB signaling pathway. The activation of cerebral NF-κB signaling pathway 
induced decreased basal and apical dendritic spine density, and impaired memory 
function in the mouse model of heart failure (Meissner et al., 2015). Moreover, the 
overexpression of p65/p50 subunit induced activation of the NF-κB pathway, then 
inhibited neurite outgrowth in primary superior cervical ganglion neurons 
(Gutierrez et al., 2008). Therefore, the NF-κB pathway mediated by oxidative stress 
and Sirt1 may be involved in neuronal lesions. 
 




In resting cells, DNA is surrounded by octamer histones (such as an H3/H4 tetramer 
and two H2A/H2B dimers) to form the nucleosome (Park and Kim, 2020). During 
the process of transcription, the post-translational modification of histones, such as 
phosphorylation, methylation, and acetylation, influences the binding between the 
transcription factor and DNA sequence (De Ruijter et al., 2003). The acetylation of 
histones is regulated by histone acetyltransferases (HATs) and histone deacetylases 
(HDACs). HATs can transfer the acetyl group from acetyl-CoA into lysine residues 
of the N-terminal of histones, leading to the decreased affinity between histones 
and DNA. The hyperacetylation by HATs induces the interaction between 
transcription factors and DNA, and increase the gene expression. In contrast, 
HDACs remove the acetyl groups from lysine residues at the N-terminal of histones, 
which enhances the affinity between DNA and histones. This hypoacetylation by 
HDACs leads to a condensed structure of DNA and blocks the gene transcription 
(Ito et al., 2000, Peserico and Simone, 2010, Strahl and Allis, 2000).  
 
Histone deacetylases are sorted into classical HDAC family members and 
nicotinamide adenine dinucleotide (NAD+)-dependent HDACs (sirtuin family) 
based on the difference of conserved deacetylase domain and dependence of NAD 
as cofactors (Park and Kim, 2020). The classical HDAC, including class I HDACs, 
class II HDACs, and HDAC11, is distinguished based on their similarity with 
deacetylases in yeast. Class I HDACs include HDAC 1, 2, 3, 8, which are similar 
to the transcriptional regulator RPD3 in the yeast, and are inside the nucleus. Class 
II HDACs are homogenous with the HDA1, which is a deacetylase found in yeast. 
The class II HDACs is divided into class IIa (HDAC 4, 5,7, 9), which can move 
between the nucleus and cytoplasm in response to the cellular signals, and class IIb 
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(HDAC 6, 10), which mainly locates in the cytoplasm. The HDAC11 is similar to 
HDAC3 and HDAC8, but it contains a catalytic domain in the N-terminal and 
locates in the nucleus (Bjerling et al., 2002, Timmermann et al., 2001, Xu et al., 
2011). HDAC2 is one of the class I HDACs and cannot be cytosolic because of 
lacking the nuclear export signal (Johnstone, 2002). When HDAC2 is recruited to 
form the multiprotein complex, such as Sin3, nucleosome-remodeling deacetylase 
complex (NuRD) and Co-REST, in response to transcription factors, the 
deacetylase activity of HDAC2 is enhanced by polypeptides in that complex, such 
as MTA2 and Sds3p (Lechner et al., 2000, Zhang et al., 1999, Delcuve et al., 2012). 
Besides, the expression and activity of HDAC2 can be mediated by  
post-translational modification at the C-terminal domain part, such as 
phosphorylation, acetylation, ubiquitination, nitrosylation, and carbonylation 
(Segré and Chiocca, 2011).  
The previous study suggests that the total HDAC expression is lower in the 
dorsolateral prefrontal cortex of schizophrenia with cognitive deficits, but higher in 
the cerebral white matter, pons, and cerebellum (Gilbert et al., 2019). This indicates 
that the abnormal HDAC expression may relate to adverse effects in cognition. 
Besides, chronic administration of clozapine induced the higher mRNA level of 
HDAC2 in the frontal cortex of mice, which is an important brain region for 
cognition (Kurita et al., 2012). Moreover, the HDAC2 overexpressed mice showed 
deficits in memory formation with decreases in dendritic spine density, synapse 
number, and synaptic plasticity, whereas learning capacity and working memory 
were improved in the HDAC2 knockout mice and the mice with HDAC2 deletion 
in postmitotic forebrain neurons (Morris et al., 2013, Guan et al., 2009). Also, 
genetic silencing of HDAC2 protein rescued cognitive deficits and reinstated the 
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synaptic plasticity in rodent models of Pitt-Hopkins syndrome and Alzheimer’s 
diseases (Kennedy et al., 2016, Gräff et al., 2012, Yamakawa et al., 2017). 
Cognitive deficits (short-term spatial memory) and synaptogenesis impairments 
induced by antipsychotic drugs, clozapine, was ameliorated in HDAC2 knockout 
mice (Ibi et al., 2017). Besides, HDAC inhibitors (sodium valproate, vorinostat, 
LBH589, MS-275) administration restored the cognitive function in the animal 
models of aging, Alzheimer’s disease, Huntington’s disease and depression (Benito 
et al., 2015, Kilgore et al., 2010, Hockly et al., 2003, Siebzehnrübl et al., 2018, 
Covington et al., 2009). Previous researches indicate that the overexpression of 
HDAC2 induced NF-κB may contribute to neuronal lesions. Both the activation of 
the NF-κB signaling pathway and overexpression of HDAC2 can induce neuronal 
lesions (Gutierrez et al., 2008, Guan et al., 2009). The activation of the NF-κB 
signaling pathway promotes binding between the NF-κB transcription factor and 
HDAC2 promoter, resulting in overexpression of HDAC2 expression (Ibi et al., 
2017). Moreover, Guan ’s team demonstrated that HDAC2 deacetylated the histone 
3 or histone 4 at the BDNF promoter, which inhibited the BDNF expression in 
HDAC2-overexpressed mice. These findings indicate that BDNF expression could 
be downregulated by the activation of the NF-κB signaling pathway and HDAC2 
overexpression. 
 
10. Short chain fatty acids as HDAC inhibitors contribute to the 
enhancement of cognition and synaptogenesis 
The HDAC inhibitor is classified into four types, as hydroxamic acids (TSA, 
SAHA), short-chain fatty acid (butyrate, propionate), cyclic tetrapeptides/epoxides 
(Trapoxin), and benzamides (CI-994, MS-275) (De Ruijter et al., 2003). The 
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treatment of SAHA improved memory deficits and enhanced synaptic plasticity in 
HDAC2 overexpressed mice (Guan et al., 2009). It is demonstrated that the chronic 
administration of SAHA upregulated the signal pathway related to the neurogenesis 
and synaptogenesis in the frontal cortex of mice (de la Fuente Revenga et al., 2018). 
The administration of CI-994 enhanced the synaptic plasticity and synaptogenesis 
in the hippocampus of mice (Gräff et al., 2014). Dietary short chain fatty acids 
(SCFAs), including butyrate, propionate, and acetate, are metabolites produced by 
the gut microbiome on fermentable fibers (Kim et al., 2018, Silva et al., 2018, 
Soliman and Rosenberger, 2011). SCFAs can serve as HDAC inhibitors. For 
example, butyrate is one of the effective inhibitors against HDAC with 80% 
inhibitory efficiency, while the propionate only has 60% (Kasubuchi et al., 2015). 
It is confirmed that two molecules of butyrate can occupy the pocket, which is a 
hydrophobic cleft containing a zinc atom, on the surface of HDACs, and inhibit the 
deacetylase activity of HDACs (Davie, 2003). In mouse models of dementia, 
injection of butyrate reinstated learning and long-term memory ability, and 
enhanced the protein level related to the formation of synapse and dendrites 
(Fischer et al., 2007). The administration of sodium butyrate improved behavioral 
despair in mouse models of depression and upregulated BDNF transcription in the 
frontal cortex (Schroeder et al., 2007). Sodium butyrate has shown inhibition 
effects of recombinant HDAC2 (Bradner et al., 2010, Vogelauer et al., 2012, 
Kilgore et al., 2010). However, the inhibition effect of sodium butyrate in neurons 
has not been investigated. 
 
11. Summary 
Although antipsychotic drugs have beneficial effects on the control of psychotic 
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symptoms in schizophrenic patients, many clinical records and studies imply that 
long-term and higher dosage of antipsychotics may induce cognitive deficits in 
schizophrenic patients and animal models. Moreover, it is reported that lifetime 
intake of antipsychotics induces the loss of cortical grey matter volume. 
Furthermore, animal studies indicate that the cognitive defects caused by 
antipsychotic drugs may be due to decreases in neurite outgrowth and mature 
dendritic spine density. The previous study suggest that the oxidative stress and 
alteration of Sirt1, NF-κB signaling pathway, and HDAC2 results in cognitive 
deficits and neuronal lesions. However, it is unknown if these molecules are 
involved in antipsychotic drugs induced neuronal lesions. Sodium butyrate is one 
of SCFAs and inhibits the deacetylase activity of HDAC2. Studies have been 
reported the neuroprotection of the sodium butyrate, such as the promotion of 
neurite outgrowth, enhancement of synaptogenesis, and elevation of BDNF 
expression. However, it is unknown that if butyrate can attenuate neuronal lesions 
induced by antipsychotic drugs.  
 
12. Aim and hypothesis 
 
This project aimed to examine if olanzapine could induce neuronal lesions and alter 
ROS level, Sirt1 expression, NF-κB signaling pathway, and HDAC2 expression. 
Furthermore, the effect and underlying mechanism of sodium butyrate in the 
prevention of neuronal damages induced by olanzapine were examined. 
We hypothesize that olanzapine can result in neuronal damages, and induce 
oxidative stress, lower level of Sirt1, activation of NF-κB signaling pathway and 
overexpression of HDAC2 (Figure 1-3). Furthermore, the treatment of sodium 
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butyrate may attenuate neuronal lesions induced by olanzapine via the inhibition of 
oxidative stress, the elevation of decreased Sirt1 expression, suppression of the 
activated NF-κB signaling pathway, blocking of deacetylase activity of HDAC2 
and inhibition of overexpressed HDAC2. 
  
Figure 1-3 The proposed mechanism of neurite lesions induced by olanzapine. The oxidative 
stress and downregulated Sirt1 induced activation of the NF-κB signaling pathway, thereby 









Schizophrenia is a heritable psychotic disorder and affects about 1% population 
around the world. Antipsychotic drugs are the widely used medication for 
schizophrenic patients with significant efficacy in positive symptoms, like 
delusions and hallucinations, and negative symptoms, as social withdraw and lack 
of motivation (Leucht et al., 2009, Lally and MacCabe, 2015). Both first-generation 
antipsychotics (FGAs) and second-generation antipsychotics (SGAs) relieved 
psychotic symptoms (Miyamoto et al., 2012). However, a 9-year follow-up study 
revealed that the cognitive deficits, as poorer verbal learning and working memory, 
occurred in schizophrenic patients with chronic administration of antipsychotic 
drugs (Husa et al., 2014). Also, the magnetic resonance images showed that the 
cortical grey matter volume and thickness were decreased in schizophrenic patients 
with chronic administration of antipsychotic drugs (Vita et al., 2015, van Haren et 
al., 2011). In animal studies, the deficit in short-term memory and decreased 
cortical volume were showed in rats with chronic treatments of antipsychotic drugs 
(Rosengarten and Quartermain, 2002, Schröder et al., 2005, Vernon et al., 2011). 
These findings suggest that decreased dendritic spine density and decreased neurite 
outgrowth may contribute to the cognitive impairments in schizophrenia (Glausier 
and Lewis, 2013, Huang and Song, 2019). Neuronal lesions induced by 
antipsychotic drugs, such as haloperidol and clozapine, were evidenced by 
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decreases in neurite outgrowth, mature spine density, and spine associated protein 
expression (spinophilin) in either neurons and animals (Ibi et al., 2017, Hu et al., 
2018, Lidow et al., 2001, Ukai et al., 2004). Brain-derived neurotrophic factor 
(BDNF) is one of the neurotrophins and promotes neurite outgrowth and dendritic 
spine density (Ji et al., 2010). After the administration of antipsychotic drugs for 
more than 12 weeks, the serum level of BDNF decreased significantly in 
schizophrenia compared with that of healthy controls (Grillo et al., 2007). However, 
the molecular mechanism of antipsychotic drugs-induced neurite lesion and BDNF 
deficits is still not clear.  
 
Sirtuin 1 (Sirt1) is one of the nicotinamide adenine dinucleotide (NAD+)-dependent 
deacetylases, which can regulate the neurite outgrowth and dendritic spine 
morphology (Sugino et al., 2010, Codocedo et al., 2012). The Sirt1 knockdown 
mice showed poorer memory performance and impaired spatial learning with 
decreased spine density and downregulated BDNF expression in the brain region 
of the hippocampus (Gao et al., 2010). Another study demonstrated the decreased 
branch point, dendritic length, and synaptic complexity in Sirt1 knockout mice 
(Michán et al., 2010). It was confirmed that schizophrenic patients with SGAs 
medication showed decreased plasma levels of BDNF and Sirt1 (Fang et al., 2019). 
Therefore, whether the expression of Sirt1 and BDNF altered by antipsychotic 
drugs involved in neuronal lesions requires further investigation.  
 
Oxidative stress is caused by the imbalance between toxic reactive oxygen species 
(ROS, pro-oxidants) and antioxidants. Also, ROS is predominately generated from 
mitochondria (Muller, 2000). It has been confirmed that the higher level of ROS in 
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plasma, lower levels and decreased catalytic activity of antioxidant enzymes in 
plasma, and declined BDNF level in serum were found in schizophrenic patients 
compared with the control group (Gonzalez-Liencres et al., 2014, Zhang et al., 
2015). Also, schizophrenic patients with administration of antipsychotic drugs for 
over six months showed the lower antioxidant level in plasma and cognitive 
impairments, as deficits in attention and immediate memory (Zhang et al., 2012). 
Moreover, oxidative stress induced by the treatment of hydrogen peroxide 
decreased neurite outgrowth in primary retinal ganglion cells (Hong et al., 2014). 
These findings indicate that oxidative stress may be involved in the antipsychotic 
drug-induced neuronal lesions. 
 
Nuclear factor-κappa B (NF-κB) is one of the transcription factors and regulates 
apoptosis and inflammation. The inactive form of NF-κB is comprised of p65/p50 
subunits (transcription factor dimer) and the NF-κB inhibitor (IκB) (Mattson and 
Camandola, 2001). Phosphorylation of IκB induces its ubiquitination and 
degradation, which results in the liberation of the p65/p50 complex. Furthermore, 
phosphorylation of the p65 subunit leads to the translocation of NF-κB into the 
nucleus to regulate the transcription of target genes (Huang et al., 2010). In addition, 
researchers found that oxidative stress and Sirt1 inhibition can stimulate the 
translocation of NF-κB directly (Gough and Cotter, 2011, Yeung et al., 2004). It is 
known that there is the interaction between Sirt1 and oxidative stress, as Sirt1 
stimulates the antioxidant expression and ROS regulates the expression and activity 
of Sirt1 (Salminen et al., 2013). It is confirmed that the activation of the NF-κB 
pathway led to decreased expression of proteins related to neurite outgrowth and 
synaptic plasticity, including BDNF, synaptophysin, and PSD95, in hippocampal 
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neurons (Zhang et al., 2020). With four weeks of treatment with risperidone, one of 
SGAs, first-episode schizophrenic patients showed hyperactivation of NF-κB 
pathway in peripheral blood mononuclear cells (Song et al., 2009). Therefore, the 
interplay between oxidative stress and Sirt1 may be involved in the activation of 
the NF-κB signaling pathway in the cell model of antipsychotic drug-induced 
neuronal lesions.   
 
Histone deacetylase 2 (HDAC2), one of class I HDAC enzymes, can remove the 
acetyl groups from lysine residues of histones. HDAC2 is involved in the inhibition 
of synaptic excitation and synapse formation (Hanson et al., 2013). For example, 
the overexpressed HDAC2 in hippocampal neurons decreased dendritic complexity 
and reduced dendritic spine density, especially in mushroom-shaped spine 
involving in memory performance (Liu et al., 2017). Moreover, the HDAC2 
overexpressed mice showed learning and spatial working memory impairments 
with decreased synaptic spine density (Guan et al., 2009). Chronic administration 
of clozapine (SGA) increased HDAC2 expression and lowered mushroom-shaped 
spine density in mice (Ibi et al., 2017). Moreover, knockdown of HDAC2 increased 
the mRNA level of BDNF in SH-SY5Y cells (Sartor et al., 2019). Therefore, 
HDAC2 may be involved in the reduction of BDNF expression and neurite lesions 
induced by antipsychotic drugs.  
 
The SH-SY5Y cell line is one of the most commonly used neuroblastoma cell lines 
for neuroscience research (Kovalevich and Langford, 2013). The differentiated  
SH-SY5Y cell represents neuronal properties, such as extensive outgrowth neurites 
and increased expression of BDNF related to the neuritogenesis (Cheung et al., 
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2009). By using this cell model, we examined the direct effect of different 
concentrations of olanzapine, one of the most commonly prescribed antipsychotic 
drugs (Ashcroft et al., 2002), on neurite outgrowth. The underlying mechanism 
associated with ROS, Sirt1, NF-κB, HDAC2, and BDNF were also examined in 
response to olanzapine in the neurons. 
 
Materials and Methods 
 
1. Cell culture and treatment 
 
The undifferentiated neuroblastoma cell line SH-SY5Y was established in Prof. 
Huang’s lab, the University of Wollongong, Australia. The SH-SY5Y cell was 
cultured in Dulbecco’s Modified Eagle Medium mixed with F12 supplementation 
(DMEM/F12, Life Technologies) with 10% heat-inactivated fetal bovine serum 
(FBS, Gibco), and 1% penicillin-streptomycin (P/S, Thermofisher) under the 
condition of 37°C in 95% air/5% CO2. For differentiation, the cell was seeded in 
the culture plate, which was coated with MaxGel™ ECM (1:100, E0282, Sigma 
Aldrich) diluted in cold medium without serum for one-hour incubation. The 
following day, the medium was replaced with DMEM/F12 containing 10μM 
retinoic acid (RA, R2625, Sigma Aldrich), 1% FBS, and 1% P/S for 24 hours. The 
differentiated neuroblastoma cell was exposed to different concentrations of 
olanzapine (11937, Cayman Chemical). The neurite length for SH-SY5Y cells was 
determined with the real-time IncucyteZoom System and analysed by Neurotracker 
software (Essen BioScience). The stock solution of olanzapine and RA were 
dissolved in dimethyl sulfoxide (DMSO, Sigma Aldrich, St Louis, MO, USA) 
 
2. MTT assay 
 
For each well of 96 well plates, two thousand SH-SY5Y cells were seeded. After 
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24 hours of differentiation, neuroblastoma cells were exposed to 0, 0.025, 0.05, 
0.075, 0.1, 0.125, 0.15, 0.3, 0.5mM olanzapine for 24 hours, 10μl 5mg/ml  
3-[4,5 dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide (MTT, 21795, 
Cayman Chemical) stock solution was added into each well containing 100μl fresh 
medium and incubated for 4 hours at 37°C. After the supernatant was replaced by 
200μl DMSO in each well, the plate was put in an orbital shaker for 15 minutes. 
The absorbance at the wavelength of 590nm was determined by SpectraMax 
Plus384 absorbance microplate reader (Molecular Devices). The cell viability was 
calculated as the percentage of fluorescence intensity of olanzapine-treated cells 
relative to that of the control group. 
 
3. Gene transfection 
 
The pCMV4 NF-κB p65 plasmid (RRID: Addgene_21966) and pCMV4 NF-κB 
p50 plasmid (RRID: Addgene_21965) were gifts from Warner Greene (Ballard et 
al., 1992). The SH-SY5Y cell was transfected by using lipofectamine™ 2000 
transfection Reagent (11668019, Invitrogen) following the manufacturer’s 
instruction. Briefly, SH-SY5Y cells were seeded in 6 well plates and incubated 
overnight. The 4μg plasmid and the 10μl lipofectamine reagent were separately 
mixed with 250μl DMEM/F12 medium without serum and incubated at room 
temperature for 5 minutes. Then the diluted plasmid and lipofectamine reagent were 
mixed gently and incubated for another 20 minutes. The mixture was added into 
each well containing 2ml fresh culture medium. After the incubation for 6 hours, 
the transfection medium was replaced by the fresh culture medium for 24 hours to 




4. Western blot 
 
For each well of 6 well plate, a total of 5ｘ105 SH-SY5Y cells were seeded and 
differentiated for 24 hours. After SH-SY5Y cells were treated with different 
concentrations of olanzapine and lysed with homogeneous buffer (Appendix), the 
lysate was put on the ice for one hour. Then, the supernatant after centrifugation of 
5 minutes at 5000rpm was stored at -80°C. The protein concentration for each 
sample was determined by using the DC-protein assay kit (500-0116, Bio-rad) and 
detected with SpectraMax Plus384 absorbance microplate reader at the wavelength 
of 750nm. Laemmli buffer mixed with 12μg protein derived from SH-SY5Y cells 
was heated at 95°C for 5 minutes. The sample was loaded into the 10% SDS-PAGE 
gels (5678025, Bio-rad) for separation (120 voltage for 80 minutes at room 
temperature), and then transferred into polyvinylidene Difluoride (PVDF) 
membranes (1620177, Bio-rad) (100 voltage for 60 minutes at 4°C). The membrane 
was blocked with 5% skim milk in TBST buffer containing 150 mM NaCl, 10 mM 
Tris, and 0.075% Tween‐20 (pH 7.5), at room temperature for 1 hour. The 
membrane was incubated with primary antibody as HDAC2 (3F3), NF-κB p65 
(D14E12), NF-κB1 p105/p50 (D4P4D), Sirt1 (1:1000, #5113, #8242, #24961, Cell 
Signaling Technologies), BDNF (N20) (1:200, sc-546, Santa Cruz Biotechnology), 
p-NFκB p65 Antibody (Ser 536) (1:200, sc-33020, Santa Cruz),and anti-β-actin 
(1:3000; Millipore) dissolved in 1% skim milk in TBST buffer at 4°C overnight. 
The secondary antibody as goat anti-mouse (1:3000, 31460, Invitrogen) and goat 
anti-rabbit (1:3000, AP308P, Millipore) was added into the membrane for 1 hour at 
room temperature. The membrane was detected by using the Enhanced 
Chemiluminescence (ECL) western blotting detection reagent (GERPN2209, GE 
Healthcare) under the Amersham Gel Imager (GE Healthcare). The density of 
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bands was analysed with Quantity One Software (Bio-Rad). 
 
5. Detection of reactive oxygen species (ROS) levels 
 
The intracellular and mitochondrial ROS levels were measured by using  
2’,7’-Dichlorofluorescein diacetate (DCFDA, 20656, Cayman Chemical), and 
Mitosox (M36008, Thermofisher), respectively. In brief, after 1ｘ105 SH-SY5Y 
cells were seeded in each well of 12 well plate and treated with 100μM olanzapine 
for 24 hours and then stained with 10μM DCFDA and 5μM Mitosox dissolved in 
phosphate-buffered saline (PBS) for 30 minutes and 15 minutes in the dark, 
respectively. After washed three times, the fluorescence was detected by the Accuri 
C6 flow cytometer (BD Bioscience), and stained cells were imaged by using the 




GraphPad Prism 5 (GraphPad Software) was used for statistical analysis. The  
one-way analysis of variance (ANOVA) followed by Turkey’s post hoc test was 
used for comparisons of multiple groups. The analysis between two groups was 
used the unpaired t-test for comparisons. The Data was shown as mean ± SEM, and 




1. Olanzapine induces impairments in neurite outgrowth in SH-SY5Y cells 
 
Firstly, MTT assay was used to determine the cell viability of SH-SY5Y cells with 
the treatment of olanzapine (0μM to 500μM) for 24 hours. Olanzapine affected  
SH-SY5Y cell viability in a dose-dependent manner, but low doses of olanzapine 
(lower than 150μM) had no significant effects on cell viability (Figure 2-1A). To 
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investigate whether the olanzapine can induce lesions in neurite outgrowth, the 
neurite length was real-time measured by Incucyte after SH-SY5Y cells treated 
with olanzapine (<150μM) for 24hours. The neurite length was shortened by 
olanzapine in a dose-dependent manner (Figure 2-1B). Compared with the control 
group, the neurite length was reduced to about 74%, 70%, 57%, 32%, 30% after 
treatment with olanzapine at 25μM, 50μM, 75μM, 100μM, and 125μM, 
respectively. Also, the representative image showed that neurite outgrowth in  
Figure 2-1 Olanzapine (Olan) shortens the neurite length but does not affect cell viability of 
SH-SY5Y cells. A) Norminalized cell viability of SH-SY5Y cells exposed to different 
concentrations of olanzapine ranging from 0 to 0.5mM for 24 hours. The data was analysed by 
one-way ANOVA and shown as mean ± SEM. N = 6. ***p < 0.001, versus the control group. B) 
The change of neurite length of SH-SY5Y cells treated with different concentrations of olanzapine 
for 24 hours. The data was shown as mean ± SEM and analysed by one-way ANOVA. N = 12. 
***p < 0.001, versus the control group. C) Representative images of SH-SY5Y cells treated with 
olanzapine for 24 hours. Scale Bar = 150µm.  
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SH-SY5Y cells was significantly affected after the treatment with 100μM 
olanzapine for 24 hours compared with the control group (Figure 2-1C). These 
results suggest that olanzapine (<150μM) can impair the neurite outgrowth in 
neurons, although it does not induce neuron loss. 
 
2. Olanzapine results in oxidative stress and downregulation of Sirt1 in  
SH-SY5Y cells 
 
Oxidative stress has been reported to be associated with neurite outgrowth lesions 
and impaired neurogenesis (Fukui et al., 2012, Suzukawa et al., 2000, Yuan et al., 
2015). Since olanzapine-induced neurite lesions were observed, the oxidative stress 
marker, the level of ROS, was examined in SH-SY5Y cells after the treatment of 
olanzapine. The intracellular and mitochondrial ROS biomarker, DCFDA and 
Mitosox, were used. After treatment with 100μM olanzapine for 24 hours, the 
fluorescence intensity of DCFDA significantly increased by 50% approximately in 
SH-SY5Y cells examined by flow cytometry (Figure 2-2A). The intracellular ROS 
accumulation induced by olanzapine was further confirmed by the measurement of 
fluorescence intensity of DCFDA in neurons by the fluorescence microscopy 
(Figure 2-2C). The fluorescence intensity of Mitosox detected by flow cytometry 
and fluorescence microscopy was higher in olanzapine-treated cells compared with 
the control group, indicating olanzapine increased ROS in mitochondria  
(Figure2-2B, D). It is reported that Sirt1 is negatively affected by ROS 
accumulation (Chen et al., 2013). We further found that the Sirt1 level significantly 
decreased by 30% approximately after olanzapine treatment in SH-SY5Y cells 
compared with the control group (Figure 2-2E). These results suggest that 
olanzapine can induce oxidative stress in the neurons with increased ROS 
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production and decreased Sirt1 expression. 
Figure 2-2 Olanzapine (Olan) induces oxidative stress and decreases Sirt1 expression. The 
quantification of fluorescence intensity of olanzapine-treated SH-SY5Y cells stained with A) 
DCFDA (FITC) and B) Mitosox (PE) detected by flow cytometry. The corresponding histogram of 
flow cytometry was shown. Black line, the control group, red line, the olanzapine group.  
N = 4. The data was shown as mean ± SEM and analysed by unpaired t-test. *p < 0.05,  
***p < 0.001, versus the control group. Representative images of olanzapine-treated SH-SY5Y cells 
stained with C) DCFDA and D) Mitosox detected by the fluorescence microscopy. Scale  
bar = 100μm. E) The change of protein level of Sirt1 in SH-SY5Y cells after treatment with 
olanzapine for 24 hours. The data was shown as mean ± SEM and analysed by unpaired t-test.  




3. Olanzapine increases the NF-κB level in SH-SY5Y cells  
 
The oxidative stress markers ROS have been reported to regulate the NF-κB 
signaling pathway (Salminen et al., 2013). Following the finding that  
olanzapine-induced oxidative stress, the protein expression of NF-κB subunits, as 
p50 and p65, were examined by western blot in SH-SY5Y cells. The protein level 
Figure 2-3 Olanzapine (Olan) stimulates the upregulation of p65 and phosphorylated p65. 
The quantification of the protein level of A) p65, B) p50 in SH-SY5Y cell after treatment with 
different concentrations of olanzapine for 24 hours. The data was shown as mean ± SEM and 
analysed by one-way ANOVA. N = 4. *p < 0.05, **p < 0.01, versus the control group. C) 
Representative images of western blot of p65 and p50 protein. D) The change of protein level of 
phosphorylated p65 in SH-SY5Y cells exposed to olanzapine for 24 hours. N = 4. Data was shown 
as mean ± SEM and analysed by one-way ANOVA. *p < 0.05, versus the control group. E) 
The representative image of the western blot of the phosphorylated p65. 
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of p65 was significantly increased after olanzapine treatment for 24 hours at 100μM 
and 125μM (Figure 2-3A, C). However, the p50 protein level was not significantly 
affected by olanzapine (Figure 2-3B, C). Furthermore, the phosphorylated p65 
increased significantly in neuroblastoma cells with the treatment of 100μM 
olanzapine (Figure 2-3D, E), suggesting the increased translocation of NF-κB 
transcription factor into the nucleus. 
 
4. Olanzapine increases HDAC2 expression in SH-SY5Y cells  
 
It has been reported that the HDAC2 protein level can be regulated by the NF-κB 
pathway (Ibi et al., 2017). The results showed that olanzapine treatment at 100μM 
and 125μM increased the HDAC2 protein level in SH-SY5Y cells (Figure 2-4A, 
B). Next, p65 and p50 plasmids were transfected into SH-SY5Y cells to investigate 
if NF-κB could regulate the HDAC2 expression. Both upregulation of p65 and 
p65/p50 expression significantly increased the HDAC2 level by 50% 
approximately compared with the control group (Figure 2-4C, D). However, when 
cells were transfected with p50 plasmid only, there was no difference in HDAC2 
level compared with the control group. Overall, these results indicate that the  
NF-κB subunit, p65, may contribute to the overexpression of HDAC2 protein 












Figure 2-4 Olanzapine induces overexpression of HDAC2 mediated by p65. A) 
Quantification of protein level of HDAC2 in SH-SY5Y cells treated with different 
concentrations of olanzapine for 24 hours. The data shown as mean ± SEM and analysed by 
one-way ANOVA. N = 4. *p < 0.05, versus the control group. B) Representative images of 
western blot of HDAC2 protein. C) Quantification of HDAC2 expression in SH-SY5Y cells 
after transfection with C-vector, p65 plasmid, p50 plasmid, and p65/p50 plasmids for 24 hours. 
Data was shown as mean ± SEM and analysed by one-way ANOVA. N = 4. *p < 0.05, versus 
the C-vector group. D) Representative images of western blot of HDAC2, p65, and p50 in 




5. Olanzapine decreases BDNF level in SH-SY5Y cells 
 
Previous researches have shown that HDAC2 downregulates the brain-derived 
neurotrophic factor (BDNF), which is important for neurite outgrowth (Jain et al., 
2013, Hacioglu et al., 2016). Since olanzapine impaired neurite outgrowth with 
increased HDAC2 expression, the BDNF level in response to olanzapine in  
SH-SY5Y cells was examined by western blot. Olanzapine decreased the BDNF 
protein level in a dose-dependent manner (Figure 2-5A, B). After olanzapine 
treatment at 100μM and 125μM for 24 hours, the BNDF protein dropped to about 




Using the SH-SY5Y cell model, we showed that olanzapine treatment decreased 
neurite outgrowth and BDNF protein expression in a dose-dependent manner. 
Concurrently, olanzapine induced both intracellular and mitochondria ROS 
accumulation, decreased expression of Sirt1 protein, activated the NF-κB signaling 
Figure 2-5 Olanzapine (Olan) decreases the BDNF expression in SH-SY5Y cells. A) 
Quantification of protein level of BDNF in SH-SY5Y cells treated with different concentrations 
of olanzapine for 24 hours. Data was shown as mean ± SEM and analysed by one-way ANOVA. 
N = 4. *p < 0.05, **p < 0.01, versus the control group. B) Representative images of western blot 
of BDNF protein. 
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pathway, and upregulated HDAC2 protein expression. These findings suggest that 
olanzapine has direct effects on neurons to induce neuronal lesions. 
 
It has been reported that long-term administrations of antipsychotics induced 
cognitive deficits, such as impairments in verbal learning, spatial learning and 
working memory in schizophrenic patients or animal models (Elie et al., 2010, 
Husa et al., 2014, Nielsen et al., 2015, Rosengarten and Quartermain, 2002, 
Skarsfeldt, 1996). In the clinical study, the volume of cortical grey matter was 
decreased in schizophrenia patients with chronic administration of antipsychotic 
drugs (Vita et al., 2015). In an animal study, the eight weeks’ administration of 
olanzapine and haloperidol reduced cortical thickness and volume in rats (Vernon 
et al., 2014). Besides, chronic clozapine treatment impaired synaptic spine in 
cortical neurons of mice (Ibi et al., 2017). However, the effect of antipsychotics, 
especially olanzapine, on neurite morphology, have rarely been investigated in 
neurons. Importantly, the present study demonstrated that olanzapine directly 
decreased neurite outgrowth in SH-SY5Y neurons. Overall, these findings indicate 
that olanzapine and other SGAs treatment induced neurite deficits, which may 
contribute to cognitive deficits in clinical usage. 
 
It was reported that oxidative stress led to the disruption of neurite morphology and 
cytoskeletal structures in human cortical neurons (Allani et al., 2004). In the present 
study, the treatment of olanzapine for 24 hours induced ROS production both in 
cellular and mitochondrial levels in SH-SY5Y cells. Our result is supported by a 
previous study in which olanzapine triggered oxidative stress and induced 
autophagy to clear damaged mitochondria in SH-SY5Y cells (Vucicevic et al., 
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2014). Furthermore, olanzapine administration for two weeks induced oxidative 
stress, evidenced by the decreased total antioxidant amount and the increased total 
oxidant amount in the liver of rats (Bilgic et al., 2017). Administration of clozapine 
for 28 days increased mitochondrial ROS level and protein carbonyls (oxidized 
protein, another biomarker for oxidative stress) in the hippocampus of rats 
(Polydoro et al., 2004, Schröder et al., 2005). Oxidative stress dramatically induced 
a loss of learning and memory function in mice, while ROS scavengers prevented 
cognitive impairments (Kamsler and Segal, 2003, Liu et al., 2003). Therefore, 
antipsychotics induced oxidative stress in neurons may contribute to neurite 
outgrowth lesions, thereby inducing cognitive impairments.  
 
Sirt1 is essential for neurodevelopment and neurogenesis (Herskovits and Guarente, 
2014). It is reported that excessive ROS level results in inhibition of Sirt1 activity 
and downregulation of the mRNA and protein level of Sirt1 (Nasrin et al., 2009, 
Yamakuchi et al., 2008, Hulsmans et al., 2011), while, the Sirt1 deacetylates the 
specific transcriptional factors to regulate the antioxidant gene expression (Pardo 
et al., 2011, Hori et al., 2013), suggesting there is a crosstalk between Sirt1 and 
ROS. Consistently, in the present study, we not only found olanzapine increased 
ROS level, but also found the Sirt1 level significantly decreased in SH-SY5Y cells. 
It was reported that inhibition of Sirt1 by siRNA induced shorter neurite length, 
decreased branch numbers, and lower dendritic spine density in neurons (Hisahara 
et al., 2008, Guo et al., 2011). In Sirt1 knockdown mice, memory performance and 
spatial learning were damaged (Gao et al., 2010). In contrast, overexpressed Sirt1 
in neurons improved neuronal cell survival (Kim et al., 2007). Also, they found that 
the resveratrol, a Sirt1 activator, prevented the impairment in learning capability in 
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mouse models of Alzheimer’s disease. Therefore, oxidative stress and 
dysregulation of Sirt1 may be interfered with each other to mediate neurite deficits 
induced by olanzapine in neurons. 
 
The present study found that olanzapine significantly increased NF-κB levels, 
especially the p65 subunit and its phosphorylation level in the neurons. Consistently, 
the recent research showed that olanzapine treatment for eight days activated the 
NF-κB signaling pathway in the hypothalamus of rats (He et al., 2019). It has been 
reported that oxidative stress by exogenously adding hydrogen peroxide resulted in 
phosphorylation of p65, and then phosphorylated p65 translocated into the nucleus 
to activate the NF-κB downstream signaling (Canty et al., 1999, Takada et al., 2003). 
Besides, ROS can stimulate the degradation of the NF-κB inhibitor, IκBα (Takada 
et al., 2003), that can bind with p65 and p50 subunits. It is demonstrated that p65 
is the direct target of Sirt1. For example, Sirt1 deacetylated the p65 subunit at the 
lys310 site, so that the translocation capability of p65 was inhibited (Yeung et al., 
2004, Kauppinen et al., 2013). Therefore, the activation NF-κB signaling pathway 
induced by olanzapine may attribute to the accumulation of ROS and decreased 
Sirt1 expression.  
 
HDAC2 regulates synaptic plasticity and memory formation (Morris et al., 2013). 
We found that olanzapine increased HDAC2 levels in SH-SY5Y neurons. 
Previously, clozapine was reported that it elevated the HDAC2 protein level 
resulting in decreased mature spine densities in mice, which was attributed to the 
binding between the NF-κB transcription factor and HDAC2 promoter (Ibi et al., 
2017). Our present studies confirmed that p65 overexpression induced higher 
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expression of HDAC2 in SH-SY5Y cells, which suggested that the HDAC2 was 
downstream of the NF-κB signaling pathway. In HDAC2 overexpressed mice, the 
memory formation was impaired significantly, and the dendritic spine density was 
decreased as well. However, HDAC2 knockout mice showed increased dendritic 
spine density inducing the synaptogenesis (Guan et al., 2009). Therefore, the 
upregulation of HDAC2 induced by olanzapine in neurons may play an important 
role in neurite lesions, leading to cognitive impairments.  
 
BDNF is an important neurotrophic factor for neurite outgrowth (Kellner et al., 
2014). We demonstrated that olanzapine treatment significantly decreased BDNF 
levels in SH-SY5Y neurons. Although, the exact mechanism is not very clear, it 
was reported that HDAC2 decreased acetylation of histone 3 and 4 near BDNF 
promoters to inhibit the expression of BDNF in the brain of mice (Guan et al., 2009). 
Therefore, a decreased level of BDNF level in the neurons treated with olanzapine 
in the present study may be due to excess HDAC2 bind with histone 3 and histone 
4 to reduce the BDNF level. Furthermore, it has been reported that the BDNF level 
is correlated with Sirt1 expression and oxidative stress. Schizophrenic patients with 
poorer cognitive function showed lower BDNF and Sirt1 levels in plasma (Fang et 
al., 2019). In addition, it was confirmed that oxidative stress and a lower level of 
BDNF were shown in schizophrenic patients with antipsychotics medication 
(Kapczinski et al., 2008, Zhang et al., 2015). Therefore, decreased BDNF level 




The present study showed that olanzapine induced neuronal lesions with decreased 
BDNF expression. It was confirmed that the treatment of olanzapine increased ROS 
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production and downregulated Sirt1, which may be involved in the activation of 
the downstream NF-κB signaling pathway (Figure 2-6). Furthermore, 
overexpression of NF-κB subunit p65 significantly induced HDAC2 protein level 
in neurons, suggesting that the upregulation of HDAC2 expression induced by 
olanzapine is attributed to the activation of the NF-κB signaling pathway. The 
overexpression of HDAC2 in response to olanzapine treatment may contribute to 
the genetic regulation of BDNF transcription via histone deacetylation. 
  
Figure 2-6 Proposed mechanism of olanzapine induced neuronal lesions in vitro. Olanzapine 
results in oxidative stress and downregulation of Sirt1, which could activate the NF-κB signaling 
pathway. The NF-κB transcription factor binds with HDAC2 promoter and upregulates HDAC2 
expression. The overexpressed HDAC2 may deacetylated histones near BDNF promoter to 




Sodium butyrate inhibits HDAC2 activity and attenuates the 




Chronic administration of antipsychotic drugs has been reported that it is associated 
with cognitive deficits in schizophrenia and caused cognitive impairments in 
animal models (Husa et al., 2014, Rosengarten and Quartermain, 2002, Schröder et 
al., 2005). It is considered that the cognitive deficit is due to the neuronal lesion 
(Huang and Song, 2019, Glausier and Lewis, 2013). The neuronal lesion, as 
decreased neurite length, reduced spine density and lower protein expression of 
brain-derived neurotrophic factor (BDNF), was found in cortical neurons and 
hippocampus of rats treated with different kind of antipsychotic drugs (Hu et al., 
2018, Ibi et al., 2017, Lidow et al., 2001, Ukai et al., 2004, Bai et al., 2003). Also, 
previous studies in Chapter 2 showed that olanzapine, one of antipsychotics, 
resulted in the reduction in neurite outgrowth and BDNF protein expression in  
SH-SY5Y cells. Therefore, targeting BDNF and its upstream signaling molecules 
may counteract the neuronal lesion and cognitive impairments induced by 
antipsychotic drugs.  
 
It was proved that histone deacetylase (HDAC) inhibitors, such as Trichostatin A 
(TSA) and Vorinostat (SAHA), possess the neuroprotective capacity and enhance 
cognitive functions (Gaub et al., 2010, Shukla et al., 2016, Guan et al., 2009). Short 
chain fatty acids (SCFAs), like butyrate, propionate, and acetate, are considered as 
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HDAC inhibitors. SCFAs are products of intestinal microbiota metabolism of 
dietary fibers. It was proved that SCFAs or dietary fibers supplementation improved 
neurodevelopment and cognition (Lei et al., 2016, Hu et al., 2018, Khan et al., 2015, 
Lee et al., 2001). The up-take rate of butyrate to the brain is higher than other 
SCFAs (Oldendorf, 1973, Dalile et al., 2019). Administration of sodium butyrate 
restored the learning and memory capacities in mouse models of Alzheimer’s 
disease (Fischer et al., 2007). Sodium butyrate administration improved the 
neuronal degeneration induced by traumatic brain injury in mice (Li et al., 2016). 
The supplementation of sodium butyrate relived the depression-like behaviors and 
enhanced the lower expression of BDNF in mice exposed to chronic restraint stress 
(Han et al., 2014). Moreover, the treatment of sodium butyrate promoted 
differentiation of PC12 pheochromocytoma cells and induced increases in dendritic 
spine density and branching (Suzuki-Mizushima et al., 2002, Takuma et al., 2014, 
Yoo et al., 2011). These results suggest that the sodium butyrate, as an HDAC 
inhibitor, may protect neurons from neuronal damages induced by olanzapine. 
Furthermore, HDAC2 mediates the impairment of synaptogenesis and cognition. 
HDAC2 overexpressed mice showed cognitive deficits, decreased spine density, 
and synapse number, while HDAC2 deficient mice showed improvement in 
learning capacity and synapse formation (Guan et al., 2009). It was confirmed in 
Chapter 2 that olanzapine induced short neurite outgrowth with overexpression of 
HDAC2. Although it is reported that butyrate inhibited HDAC2 in the colon tissue 
and other peripheral cells (Fellows et al., 2018, Kim et al., 2018, Du et al., 2020), 
it is unknown if butyrate can inhibit the deacetylase activity or expression of 




Oxidative stress induces neuronal lesions, such as decreased spine density and 
reduced neurite outgrowth (Avila-Costa et al., 1999, Ashabi et al., 2013). 
Furthermore, the sirtuin 1 (Sirt1) inhibition led to impairment in neurite outgrowth, 
axonogenesis, synaptogenesis, and cognition (Sugino et al., 2010, Li et al., 2013, 
Liu et al., 2013, Gao et al., 2010). The interplay between oxidative stress and Sirt1 
is shown below. Oxidative stress can result in inhibition of the deacetylase activity 
of Sirt1 and stimulate its degradation (Salminen et al., 2013). Sirt1 can stimulate 
the antioxidant defense to block oxidative stress (Alcendor et al., 2007). In Chapter 
2, it was demonstrated that olanzapine caused oxidative stress and lowered 
expression of Sirt1 with severe neurite damages. Previous researches showed that 
the administration of sodium butyrate ameliorated the oxidative stress in the lung 
tissue of rats models of lung fibrosis (Kabel et al., 2016). Furthermore, sodium 
butyrate enhanced the activity of antioxidant enzymes in the frontal cortex and 
hippocampus of rats models of mania (Valvassori et al., 2016). The sodium butyrate 
promoted the mRNA level of Sirt1 in the lymphoblastoid cell (Rose et al., 2018). 
Therefore, sodium butyrate may inhibit oxidative stress and upregulate Sirt1 to 
improve neuronal lesions. 
 
It is reported that the NF-κB signaling pathway can be activated by oxidative stress 
and lower expression of Sirt1 (Schreck et al., 1992, Van den Berg et al., 2001, 
Salminen et al., 2008b). The NF-κB signaling pathway involved in decreased spine 
density and impaired neurite outgrowth (Meissner et al., 2015, Gutierrez et al., 
2008). Translocated NF-κB inside the nucleus binds with the HDAC2 promoter and 
results in a higher expression of HDAC2 (Ibi et al., 2017). Consistently, results in 
Chapter 2 proved that the activation NF-κB signaling pathway and upregulation of 
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HDAC2 were induced by olanzapine in SH-SY5Y cells with neurite damages. 
Previous researches showed that sodium butyrate inhibited the NF-κB signaling 
pathway via a block of phosphorylation of IκBα in colorectal adenocarcinoma cells 
(COLO 205 cell line), murine monocyte/macrophage-like cells (RAW264.7 cell 
line) and mouse peritoneal macrophages (Lee et al., 2017). Butyrate downregulated 
NF-κB transcriptional activity in hippocampus slice exposed to LPS and inhibited 
neuroinflammation in primary microglia (Huuskonen et al., 2004). Therefore, 
SCFAs can inhibit the transcription mediated by NF-κB and suppress 
neuroinflammation in cancer or immune cells. However, it is still unknown if 
sodium butyrate could inhibit the NF-κB signaling pathway in neurons and 
ameliorate the olanzapine-induced neurite lesions. 
 
In the present study, we aimed to examine if sodium butyrate could prevent 
neuronal damages induced by olanzapine. Also, the underlying mechanism will be 
investigated by examination of the level of oxidative stress marker — ROS and 
Sirt1, the NF-κB signaling pathway, and enzyme activity and expression of HDAC2 
by flow cytometry, immunofluorescence, western blot, and deacetylase activity 
assay kits. 
 
Materials and methods 
 
1. Cell culture and treatments 
 
The undifferentiated neuroblastoma cell line-SH-SY5Y was established in Prof. 
Huang’s lab, the University of Wollongong, Australia. SH-SY5Y cells were grown 
in Dulbecco’s Modified Eagle Medium mixed with F12 supplementation 
(DMEM/F12, Life Technologies) with 10% heat-inactivated fetal bovine serum 
(FBS, Gibco), and 1% penicillin-streptomycin (P/S, Thermofisher) at 37°C in 95% 
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air/5% CO2. In order to stimulate differentiation, cells were seeded in the plate, 
which has been coated with MaxGel™ ECM (1:100, E0282, Sigma Aldrich) diluted 
in fresh medium for 1hour incubation. On the following day, the medium needed to 
be replaced by 1% FBS in DMEM/F12 with 10μM retinoic acid (RA, R2625, Sigma 
Aldrich) for 24 hours. 
 
According to the method published by Hilgenberg and Smith (2007), cortical 
neurons were harvested from the postnatal day 0~3 of C57BL/6J mice, which has 
been approved by the Animal Ethics Committee, University of Wollongong, 
Australia, and complied with the Australian Code of Practice for the Care and Use 
of Animals for Scientific Purposes. Briefly, the frontal cortex was dissected and cut 
into small pieces in dissection solution (Appendix). After incubation with the 5ml 
enzyme solution (Appendix) at 37°C incubator for 30 minutes, the cortical neuron 
was resuspended in Neurobasal™ medium (21103049, Gibco) with B-27™ 
supplement (17504044, Gibco), 1% P/S and 0.1 M glucose (G-8270, Sigma 
Aldrich). The cortical neuron was seeded in the glass coverslip, which had been 
coated with poly-D-lysine (p6407, Sigma Aldrich) at 4°C overnight. The  
5-fluoro-2′-deoxyuridine (F0503, Sigma Aldrich) was added to the culture medium 
to inhibit the growth of glial cells at a final concentration of 10μM after 24 hours 
of culture. 
 
The differentiated SH-SY5Y cell or the primary cortical neuron was treated with 
100μM olanzapine (11937, Cayman Chemical) for 24 hours or 3 hours with or 
without pre-treatment of sodium butyrate (5 or 10μM) (B5887, Sigma Aldrich) for 
30 minutes. SH-SH5Y cells were exposed to a range of sodium butyrate from 0 to 
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5mM for 24 hours to choose the appropriate concentration for neuroprotection. All 
the reagent was dissolved in dimethyl sulfoxide (DMSO, Sigma Aldrich). 
 
2. HDAC2 activity assay 
 
FLUOR DE LYS®-Green HDAC2 fluorometric drug discovery assay kit  
(BML-AK512-0001, Enzo Life Sciences) was used for the detection of 
recombinant HDAC2 activity exposed to a range of different concentrations of 
sodium butyrate. According to the manufacturer’s protocol, 15μl recombinant 
HDAC2 (1ng) was mixed with 25μl FLUOR DE LYS®-Green substrate (20μM) 
and 10μl different concentrations of sodium butyrate at final concentrations of 1μM, 
10μM, 50μM, 100μM, 1mM, 2mM, and 10mM in the wells of the corresponding 
microplate for 1 hour incubation at room temperature. Then 50μl FLUOR DE 
LYS®-Green developer containing 2μM TSA was added into each well to stop the 
reaction between the recombinant HDAC2 and substrates. The plate was shaken at 
room temperature for 15 minutes, and the fluorescence was determined by 
FlexStation 3 multi-mode microplate reader (Molecular Devices) with excitation 
wavelength at 485nm and emission wavelength at 528nm. The HDAC2 activity 
was calculated as the percentage of fluorescence intensity of treated groups 
compared with that of the control group.  
 
The inhibition of cell-derived HDAC2 deacetylase activity by sodium butyrate was 
detected based on the previous publication (Reddy et al., 2018). 
Immunoprecipitation was carried out to isolate HDAC2 protein from SH-SY5Y 
cells treated with 10μM sodium butyrate for 24 hours. Briefly, after the treatment 
of sodium butyrate, SH-SY5Y cells were lysed with the homogenous buffer, 
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comprising of 0.5mM β-glycerophosphate (G-9422, Sigma Aldrich), 1mM PMSF 
(P7626, Sigma Aldrich), and protease inhibitor cocktail (PIC, P-8340, Sigma 
Aldrich). After protein concentration for each sample was determined by DC 
protein assay (5000116, Bio-rad) and detected by SpectraMax Plus384 absorbance 
microplate reader at the wavelength of 750nm, 500μg total protein was dissolved 
in 200μl homogenous buffer and mixed with 1μl HDAC2 antibody (3F3) (1:200, 
#5113, Cell Signaling Technologies) at 4°C overnight. On the following day, the 
centrifuge tube containing 50μl Dynabeads™ Protein A (10002D, Thermofisher) 
was put on the magnet and washed with the homogenous buffer. The 200μl cell 
lysate with HDAC2 antibody was transferred into the tube containing magnetic 
beads and incubated with rotation at room temperature for 20 minutes. After 
washed 5 times with homogenous buffer, the 100μl 10μM  
substrate--Boc-Lys(Ac)-AMC (29682, Cayman Chemical) was added into the tube 
containing bead-antibody-HDAC2 complex. After 30 minutes of incubation at 
room temperature, 50μl of the deacetylated substrate was added into wells of the 
corresponding microplate with 50μl developer containing 100 μM trypsin (T1426, 
Sigma Aldrich) and 100 nM TSA (89730, Cayman Chemical). Then the plate was 
incubated at room temperature for more than 15 minutes. To confirm that 
olanzapine had no impact on HDAC2 activity, 15μl recombinant HDAC2 (1ng), 
25μl 10μM substrate, and 10μl olanzapine at a final concentration of 100μM were 
mixed and incubated for 30 minutes at room temperature. Then the 50μl developer 
was added into each well of corresponding microplates, and the plate was incubated 
for more than 15 minutes. The fluorescence was determined with the FlexStation 3 
multi-mode microplate reader at the excitation wavelength at 360nm and emission 
wavelength at 460nm. The HDAC2 activity was shown as the percentage of 
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fluorescence intensity of samples treated with sodium butyrate relative to that of 
the control group. 
 
3. Measurement of neurite outgrowth and spine density  
 
For differentiated SH-SY5Y cells, the neurite outgrowth was monitored via the 
real-time IncucyteZoom system and analysed by Neurotracker software (Essen 
BioScience). At 7 days in vitro (DIV7), the primary cortical neuron was treated with 
olanzapine for 24 hours with or without pre-treatment of sodium butyrate for 30 
minutes. After washed one time with phosphate-buffered saline (PBS), cortical 
neurons were fixed with 4% formaldehyde for 15 minutes. Then cells were washed 
with PBS two times and were permeablized with 0.3% Triton X-100 for 10 minutes. 
After cells were blocked with 5% normal donkey serum in 0.3% Triton X-100 for 
1 hour at room temperature, the cell was incubated with MAP2 antibody (1:800, 
M4403, Sigma Aldrich) dissolved in 1% normal donkey serum at 4°C overnight. 
The next day, the cell was incubated with secondary antibody Alexa Fluor 488-
conjugated donkey anti-mouse IgG (1:400, A-21202, Invitrogen) in 1% normal 
donkey serum for 1 hour at room temperature. The glass coverslip was mounted 
with ProLong™ Diamond Antifade Mountant (p36961, Thermofisher) and 
visualized by using a 40X oil immersion objective on DMI6500B confocal 
microscope (Leica). The ImageJ software (NIH) was used to analyse the total 
neurite length. 
 
Similarly, after cultured for 21 days in vitro (DIV21) and treated with olanzapine 
and sodium butyrate, the primary cortical neuron was fixed with 4% formaldehyde 
for 15 minutes before incubation with 0.3% Triton X-100 for 5 minutes. Then the 
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cell was stained with Phalloidin-iFluorTM 594 Conjugate (1:1000, 20553, Cayman 
Chemical) dissolved in 1% bovine serum albumin (BSA) for 90 minutes at room 
temperature. After rinsed for 3 times, the glass coverslip was mounted with 
ProLong™ Diamond Antifade Mountant and visualized by using a 63X oil 
immersion objective on DMI6500B confocal microscope. The spine density was 
calculated by using the ImageJ software. Dendritic segments that were not 
overlapped with other branches were picked 50μm away from the soma randomly 
and. More than 4 dendritic segments per cell with a total neurite length of more 
than 80μm were measured in 20 neurons per group. 
 
4. Measurement of reactive oxygen species (ROS) production 
 
SH-SY5Y cells were treated with olanzapine with or without pre-treatment of 
sodium butyrate for 24 hours. The cellular and mitochondrial ROS levels were 
determined by staining with 10μM 2’,7’-Dichlorofluorescein diacetate (DCFDA, 
20656, Cayman Chemical) and 5μM Mitosox (M36008, Thermofisher) for 30 
minutes and 15 minutes, respectively. The fluorescence intensity of the stained cell 
was detected with the Accuri C6 flow cytometer (BD Bioscience) and visualized 
with a 20X DMI8 Fluorescent Microscope (Leica). 
 
5. Real-time polymerase chain reaction (RT-PCR) 
 
The primary cortical neuron (DIV7) were treated with olanzapine with or without 
sodium butyrate for 3 hours. Messenger RNA (mRNA) was extracted with the 
Aurum™ Total RNA Mini Kit (7326820, Bio-Rad). According to the 
manufacturer’s protocol, cortical neurons were lysed with the lysis buffer 
containing 1% β-mercaptoethanol (M6250, Sigma Aldrich) and then mixed with 
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70% ethanol. Then the mixture was added into RNA binding columns, which were 
inside of 2ml capless wash tubes. After washed and centrifuged at 13000rcf for 30 
seconds, the 5μl reconstituted DNase I diluted in 80μl DNase dilution buffer was 
added in the membrane of each column for 15 minutes incubation. After washed 2 
times, the RNA binding column was transferred into a new 1.5ml capped centrifuge 
tube, and the 40μl elution buffer was added into each tube. The total mRNA was 
received after the column was incubated with elution buffer for 1 minute and 
centrifuged. 
 
The total mRNA concentration was determined with NanoDrop™ 2000 
Spectrophotometers (Thermofisher). The reverse transcription of 500ng mRNA 
sample was performed by the High-Capacity cDNA Reverse Transcription Kit 
(4368813, Applied Biosystems™). According to the manufacturer’s protocol, the 
20µl reaction system is consisted with 2µl 10X RT buffer, 0.8 µl 25X dNTP mix 
(100mM), 2µl 10X RT random primers, 1µl MultiScribeTM reverse transcriptase, 
4.2µl nuclease-free H2O and 10µl mRNA sample in 1.5ml centrifuge tube. The tube 
was placed at 25°C for 10 minutes, 37°C for 120 minutes, 85°C for 5 minutes and 
was stored at 4°C.  
 
PCR amplification was performed by using the SensiFASTTM SYBR No-ROX kit 
(BIO-98005, Bioline) and detected with QuantStudio™ 5 Real-Time PCR System 
(Thermo Fisher Scientific). Following the manufacturer’s protocol, for each well 
in a corresponding microplate, 2µl synthesized DNA template was mixed with 1µl 
forward primer, 1µl reverse primer, 6µl nuclease-free H2O and 10µl SensiFAST
TM  
SYBR No-ROX reagent. The cycling condition was set as 95°C for 2 minutes for 
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polymerase activation, and 40 repeatable cycles were adjusted as 95°C for 5 
seconds (denaturation), 60°C for 10 seconds (annealing), and 72°C for 10 seconds 
(extension). The mRNA expression level of target genes was calculated by using 
the 2−ΔΔCt method, in which the ΔΔCt is the value of ΔCt of the control group 
subtracted by that of treatment groups. All mRNA levels (Table 3-1) were 
normalized to that of Glyceraldehyde 3- phosphate dehydrogenase (GAPDH).  
 
6. Western blot 
 
After the SH-SY5Y cell was treated with olanzapine with or without pre-treatment 
of sodium butyrate for 24 hours, the cell pallet was lyzed by using the homogenous 
buffer and left on the ice for 1 hour. After the lysate was centrifuged at 5000rpm 
for 5 minutes at 4°C, the supernatant was isolated and stored at -80°C. Following 
the manufacturer’s protocol, DC protein assay (500-0116, Bio-rad) was used for 
the determination of the protein concentration for each sample. The fluorescence 
was detected by using the SpectraMax Plus384 absorbance microplate reader at the 
wavelength of 750nm. Loading samples were comprised of the laemmli buffer and 
12μg protein. After heated at 95°C for 5 minutes, the sample was loaded into the 
10% SDS-PAGE gels (5678025, Bio-rad). Following the gel electrophoresis for 
Gene Primer Sequence 
GAPDH 
Forward primer 5’-TGA-AGC-AGG-CAT-CTG-AGG-G-3’ 
Reverse primer 5’-CGA-AGG-TGG-AAG-AGT-GGG-AG-3’ 
BDNF 
Forward primer 5’-GGG-TCA-CAG-CGG-CAG-ATA-AA-3’ 
Reverse primer 5’-GCC-TTT-GGA-TAC-CGG-GAC-TT-3’ 
MAP2 
Forward primer 5’-ATG-AAG-GAA-AGG-CAC-CAC-AC-3’ 
Reverse primer 5’-AAT-AGG-TGC-CCT-GTG-ACC-TG-3’ 
PSD-95 
Forward primer 5’-GGT-GAC-GAC-CCA-TCC-ATC-TTT-ATC-3’ 
Reverse primer 5’-CGG-ACA-TCC-ACT-TCA-TTG-ACA-AAC-3’ 
Synaptophysin 
Forward primer 5’-GAA-CAA-GTA-CCG-AGA-GAA-CAA-CAA-3’ 
Reverse primer 5’-GGT-CAG-TGG-CCA-TCT-TCA-CA-3’ 
Table 3-1 The forward primer and reverse primer of target genes 
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separation at 120 voltage for 80 minutes at room temperature, the polypeptide was 
transferred into polyvinylidene difluoride (PVDF) membranes (1620177, Bio-rad) 
at 100 voltage for 60 minutes at 4°C. The 5% skim milk in TBST buffer (150 mM 
NaCl, 10 mM Tris, and 0.075% Tween‐20, pH 7.5) was used to block the membrane 
for 1 hour at room temperature. Then the membrane was incubated with the primary 
antibody, as HDAC2 (3F3), NF-κB p65 (D14E12), NF-κB1 p105/p50 (D4P4D), 
Sirt1 (1:1000, #5113, #8242, #24961, Cell Signaling Technologies), anti-β-actin 
(1:3000, Millipore) and BDNF (1:200, SC-546, Santa Cruz) dissolved in 1% skim 
milk in TBST at 4°C overnight. After washed 3 times for 5 minutes, the membrane 
was incubated with the secondary antibody as goat anti-mouse (1:3000, 31460, 
Invitrogen) and goat anti-rabbit (1:3000, AP308P, Millipore) antibody for 1 hour at 
room temperature. The band was visualized with the Enhanced Chemiluminescence 
(ECL) western blotting detection reagent (GE Healthcare) under the Amersham Gel 




GraphPad Prism 5 (GraphPad Software) was used for analysis. The one-way 
analysis of variance (ANOVA) following the Turkey’s post hoc test was used for 
comparisons between multiple groups except for sholl analysis, whereas the 
unpaired t-test was used for comparisons between two groups. For sholl analysis, 
the two-way repeated-measures ANOVA followed by Turkey’s post hoc test was 








1. Sodium butyrate prevents neurite deficits induced by olanzapine in  
SH-SY5Y cells 
 
Butyrate is the most uptake SCFAs to the brain and previously reported to increase 
neurite length in PC12 pheochromocytoma cell (Suzuki-Mizushima et al., 2002, 
Oldendorf, 1973, Dalile et al., 2019). Here, we investigated that if the sodium 
butyrate could improve the neurite outgrowth impairment induced by olanzapine in 
SH-SY5Y cells. Firstly, the neurite length of SH-SY5Y cells treated with sodium 
butyrate (0 to 5mM) was determined by the IncucyteZoom system. The result 
showed that the sodium butyrate (0 to 100μM) did not significantly affect the 
neurite length, while higher concentrations over 500μM induced a significant 
decrease in neurite outgrowth (Figure 3-1A). It is reported that the concentration 
of butyrate in human cerebrospinal fluid (CSF) is at the micromolar level (Wishart 
et al., 2018). Besides, it is confirmed that sodium butyrate at lower concentrations 
did not affect neurite length. Moreover, previously it is found that butyrate at 10μM 
inhibited the apoptosis induced by 6-hydroxydopamine (6-OHDA) in SH-SY5Y 
cells (Funakohi-Tago et al., 2018). Therefore, the clinically feasible concentration, 
as 5μM and 10μM, of sodium butyrate was used to examine the neurite length in 
the following experiments. It is found that co-administration of sodium butyrate at 
10μM and olanzapine significantly increased neurite length compared with the 
olanzapine group, while sodium butyrate at 5μM did not ameliorate the olanzapine-
induced neurite lesions (Figure 3-1B). Furthermore, live-cell images from the 
IncucyteZoom system showed that the SH-SY5Y cell treated with 10μM sodium 
butyrate and 100μM olanzapine had longer neurites compared with that of the 




Figure 3-1 Sodium butyrate (Buty) improves the neurite deficit induced by olanzapine 
(Olan) in SH-SY5Y cells. A) The change of neurite outgrowth of SH-SY5Y cells exposed to 
different concentrations of sodium butyrate for 24 hours. N = 6. The data was shown as  
mean ± SEM and analysed by one-way ANOVA. ***p < 0.001, **p < 0.001, versus the control 
group. B) The change of neurite length of SH-SY5Y cells with pre-treatment of sodium butyrate 
(5, 10µM) and the treatment of olanzapine (100µM) for 24 hours. The data was shown as  
mean ± SEM and analysed by one-way ANOVA. N = 4. ***p < 0.001, versus the control group, 
##p < 0.01, versus with the olanzapine group. C) Representative images of morphology of  
SH-SY5Y cells treated with 100μM olanzapine with or without 10μM sodium butyrate for 24 
hours. Scale bar = 150µm. 
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2. Sodium butyrate prevents decreased neurite length and spine density 
induced by olanzapine in primary cortical neurons  
 
The primary cortical neuron, as a physiological model of neurons (Nolan, 2007), 
was used to examine the protective effect of sodium butyrate on the synaptogenesis. 
After cortical neurons were cultured for 7 days, cells were treated with 10μM 
sodium butyrate prior to 100μM olanzapine for 24 hours. After stained with the 
MAP2 antibody, the neurite outgrowth was visualized and analysed. The neurite 
outgrowth of cortical neurons treated with olanzapine was shorter compared with 
the control group, whereas the pre-treatment with sodium butyrate can reverse that 
lesion (Figure 3-2A). The quantification of the total dendrite length of cortical 
neurons showed that olanzapine significantly decreased the total neurite length per 
cell compared with the control group (Figure 3-2B). However, the pre-treatment 
with sodium butyrate significantly increased the neurite length per cell from 300μm 
to 432μm approximately compared with olanzapine treatment alone group. Besides, 
the sholl analysis was used to examine the morphology of dendrites (Sholl, 1953). 
A series of concentric circles were created from the soma of cortical neurons every 
5μm, and the intersection between dendrites and circles was counted. The result 
showed a significant reduction of intersections in cortical neurons treated with 
olanzapine when compared with the control group (Figure 3-2C). However, the 
pre-treatment with sodium butyrate significantly increased the number of 
intersections in primary cortical neurons compared with the olanzapine treatment 
only group (Figure 3-2D). It indicates that sodium butyrate can prevent the deficit 
in neurite outgrowth (complexity of dendritic tree) induced by olanzapine.  
 




Figure 3-2 Sodium butyrate (Buty) reverses the decreased neurite length and spine density 
induced by olanzapine (Olan) in primary cortical neurons. A) Representative images of mouse 
cortical neurons after pre-treatement of 10µM sodium butyrate and treatment of 100µM olanzapine for 
24 hours. Scale bar = 20µm. B) Quantification of the average of total neurite length per cortical neuron 
after treatment with sodium butyrate and olanzapine for 24 hours. Data was shown as mean ± SEM 
and analysed by one-way ANOVA. 19≤ N ≤29. ***p < 0.001, versus the control group, ## p <0.01, 
versus the olanzapine group. Sholl analysis of cortical neurons after treatment with C) 100µM 
olanzapine D) with or without pre-treatment with 10µM sodium butyrate for 24 hours. The data was 
shown as mean ± SEM and analysed by two-way ANOVA. 19≤ N ≤29. ***p < 0.001, versus the 
control group, ##p < 0.01, versus the olanzapine group. E) Representative images of dendrite segments 
of DIV21 cortical neurons with treatment of olanzapine and sodium butyrate for 24 hours. Scale  
bar = 5μm. F) The quantification of basal spine density in primary cortical neurons after treatment with 
olanzapine with or without pre-treatment of sodium butyrate for 24 hours. Data were shown as  
mean ± SEM and analysed by one-way ANOVA. **p < 0.01, versus the control group, ###p < 0.001, 
versus the olanzapine group. N = 20.  
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examined in DIV21 primary cortical neurons stained with phalloidin. The result 
revealed that sodium butyrate significantly increased the spine density (mean: 0.76 
± 0.04 spines/μm) of primary cortical neurons compared with the control group 
(mean: 0.60 ± 0.02 spines/μm). Furthermore, olanzapine markedly decreased the 
spine density (mean: 0.46 ± 0.03 spines/μm) compared with the control group, 
while the pre-treatment of sodium butyrate significantly increased the spine density  
(mean: 0.70 ± 0.03 spines/μm) compared with olanzapine treatment alone group 
(Figure 3-2E, F). These results suggest the sodium butyrate protects the cortical 
neurons from the synaptogenesis impairment (neurite outgrowth and spine density) 
induced by olanzapine. 
 
3. Sodium butyrate reverses the lower expression of BDNF in neurons 
induced by olanzapine 
 
Next, the level of neurotrophic factor and synaptic proteins, BDNF, MAP2, 
synaptophysin, and PSD95, were examined in neurons in response to olanzapine 
and sodium butyrate. Olanzapine resulted in a significantly lower mRNA level of 
BDNF in primary cortical neurons compared with the control group, whereas the 
pre-treatment of sodium butyrate markedly increased mRNA level of BDNF 
compared with olanzapine treatment only group (Figure 3-3A). However, sodium 
butyrate and olanzapine did not impact the mRNA level of MAP2, Synaptophysin, 
and PSD95. At the protein level, the result of western blot showed that sodium 
butyrate inverted the decreased BDNF protein level induced by olanzapine in  
SH-SY5Y cells (Figure 3-3B, C). These observations suggest that the sodium 





4. Sodium butyrate inhibits HDAC2 enzyme activity 
 
HDAC2 is reported to inhibit BDNF expression (Guan et al., 2009). Following 
sodium butyrate increased the BDNF level in neurons exposed to olanzapine, next, 
we assessed the ability of sodium butyrate in inhibition of HDAC2 enzyme activity 
by using the recombinant HDAC2 protein and SH-SY5Y cells-derived HDAC2 
protein respectively. Different concentrations of sodium butyrate ranged from 1μM 
Figure 3-3 Sodium butyrate (Buty) reverses the downregulated mRNA level and protein level 
of BDNF induced by olanzapine (Olan). A) The change of mRNA level of BDNF, MAP2, PSD95 
and synaptophysin in primary cortical neurons with treatment of sodium butyrate (10μM) and 
olanzapine (100μM) for 3 hours. N = 4. Data was shown as mean ± SEM and analysed by  
one-way ANOVA. **p < 0.01, versus the control group, ##p < 0.01, versus the olanzapine group. 
B) The quantification of protein level of BDNF in SH-SY5Y cells treated with sodium butyrate 
and olanzapine for 24 hours. N = 4. Data was shown as mean ± SEM and analysed by one-way 
ANOVA. **p < 0.01, versus the control group, #p < 0.05, versus the olanzapine group. C) 
Representative images of western blot of BDNF protein. 
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to 10mM were react with recombinant HDAC2 protein. The activity of recombinant 
HDAC2 was significantly inhibited by sodium butyrate in a dose-dependent 
manner (Figure 3-4A). Previous results confirmed that 10μM sodium butyrate 
significantly ameliorated the olanzapine-induced neurite lesion in SH-SY5Y cells 
compared with the control group (Figure 3-1B). Therefore, whether 10μM sodium 
butyrate could inhibit HDAC2 deacetylase activity in SH-SY5Y cells was 
examined here. The HDAC2 protein derived from sodium butyrate-treated  
SH-SY5Y cells was separated from the total cell lysate by using 
immunoprecipitation, followed by incubation with substrates. The result showed 
Figure 3-4 Sodium butyrate (Buty), but not olanzapine (Olan), inhibits the HDAC2 
deacetylase activity. A) Dose response of sodium butyrate on deacetylase activity of recombinant 
HDAC2 protein. The data was shown as mean ± SEM and analysed by one-way ANOVA. N = 3. 
***p < 0.001, versus the control group. B) The change of deacetylase activity of HDAC2 in  
SH-SY5Y cells treated with 10μM sodium butyrate for 24 hours. Data was shown as mean ± SEM 
and analysed by unpaired t-test. N = 7. *p < 0.05, versus the control group. C) The change of 
enzyme activity of recombinant HDAC2 reacted with olanzapine at 100μM. Data was shown as 
mean ± SEM and analysed by unpaired t-test. 
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that the HDAC2 enzyme activity in SH-SY5Y cells was significantly blocked in 
the sodium butyrate group compared with the control group (Figure 3-4B). 
Olanzapine did not affect the HDAC2 deacetylase activity (Figure 3-4C), although 
olanzapine is found to increase the HDAC2 protein level in SH-SY5Y cells 
(Chapter 2). These results suggest that sodium butyrate is an HDAC2 enzyme 
inhibitor in neurons.  
 
 
5. Sodium butyrate does not reverse olanzapine’s effects on the ROS level 
and Sirt1 expression in SH-SY5Y cells  
It has been previously shown that the olanzapine induced higher ROS level and 
lower expression of Sirt1 protein (Chapter 2). To examine whether sodium 
butyrate could affect the ROS level, DCFDA and Mitosox staining were used to 
evaluate the intracellular and mitochondrial ROS in SH-SY5Y cells. Sodium 
butyrate did not alter the fluorescence intensity of DCFDA and Mitosox in  
SH-SY5Y cells, suggesting sodium butyrate did not affect ROS production  
(Figure 3-5A~D). Furthermore, although olanzapine increased the fluorescence 
intensity of DCFDA and Mitosox in SH-SY5Y cells, the pre-treatment of sodium 
butyrate did not attenuate olanzapine’s effects. In addition, sodium butyrate alone 
treatment did not influence the Sirt1 protein level (Figure 3-5E, F). The co-
administration of sodium butyrate and olanzapine did not restore the reduction of 
Sirt1 expression induced by olanzapine. The result indicates that sodium butyrate 
can not prevent alteration of ROS production and the Sirt1 level induced by 






Figure 3-5 Sodium butyrate (Buty) does not ameliorate the ROS accumulation and the decreased 
Sirt1 expression induced by olanzapine in SH-SY5Y cells. The quantification of fluorescence 
intensity of SH-SY5Y cells stained with A) DCFDA (FITC) and B) Mitosox (PE) after treatment with 
olanzapine and sodium butyrate for 24 hours determined by flow cytometry. The corresponding 
histogram of flow cytometry was shown. Black line, the control group, red line, the olanzapine group, 
yellow line, the combination of sodium butyrate and olanzapine group. Data was shown as  
mean ± SEM and analysed by one-way ANOVA. N = 4. *p < 0.05, **p < 0.01, versus the control 
group. Representative images of SH-SY5Y cells stained with C) DCFDA and D) Mitosox imaged by 
the fluorescence microscopy. Scale bar = 100μm. E) The quantification of Sirt1 protein level in  
SH-SY5Y cells exposed to sodium butyrate and olanzapine for 24 hours. Data were shown as mean ± 
SEM and analysed by one-way ANOVA. N = 4. *p < 0.05, compared with the control group. F) The 
representative image of the western blot of Sirt1 protein. 
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6. Sodium butyrate does not prevent the alteration of p65, p50, and HDAC2 
induced by olanzapine in SH-SY5Y cells 
 
The activation of the NF-κB pathway and the upregulation of its downstream 
protein — HDAC2 were observed in SH-SY5Y cells after treatment with 
olanzapine (Chapter 2). Here we examined that if sodium butyrate could prevent 
olanzapine’s effect on NF-κB and HDAC2 levels. The sodium butyrate alone did 
not significantly change the NF-κB subunits, p65, and p50 (Figure 3-6A~D). The 
pre-treatment of sodium butyrate did not prevent the effect of increased p65 
induced by olanzapine (Figure 3-6A). Besides, the sodium butyrate did not affect 
the HDAC2 protein level in SH-SY5Y cells (Figure 3-6E, F). Although olanzapine 
significantly increased the HDAC2 protein level, there was no significant 
difference in HDAC2 protein level between the group of sodium butyrate and 
olanzapine combination compared with the olanzapine alone group. Therefore, 
these results indicate that sodium butyrate can not prevent olanzapine’s effects on 






In this chapter, it is found that sodium butyrate prevented the neurite outgrowth 
impaired by olanzapine both in the neuroblastoma cell line (SH-SY5Y cells) and 
primary cortical neurons. Besides, the reduced total neurite length and dendritic 
spine density induced by olanzapine were restored by sodium butyrate as well. 
Figure 3-6 Sodium butyrate (Buty) cannot reverse the overexpression of p65 and HDAC2 in 
SH-SY5Y cells. Quantification of the protein level of A) p65, C) p50, and E) HDAC2 in  
SH-SY5Y cells after treatment with olanzapine and sodium butyrate for 24 hours. Data was shown 
as mean ± SEM and analysed by one-way ANOVA. N = 4. *p < 0.05, versus the control group. 
The representative image of western blot of B) p65, D) p50 and F) HDAC2. 
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Importantly, sodium butyrate reinstated neurotrophic factor, BDNF level in neurons 
exposed to olanzapine. With HDAC2 enzyme activity assay, sodium butyrate 
significantly inhibited the deacetylase activity of recombinant HDAC2 and  
SH-SY5Y cell-derived HDAC2 protein. However, sodium butyrate did not 
ameliorate olanzapine-induced oxidative stress, lower Sirt1 level, activation of the 
NF-κB signaling pathway, and higher HDAC2 protein level caused by olanzapine. 
Therefore, sodium butyrate may improve the impairment of synaptogenesis 
induced by olanzapine via inhibition of HDAC2 enzyme activity to increase BDNF 
expression, but not via regulation of oxidative stress and Sirt1expression, and 
modulation of the NF-κB signaling pathway and HDAC2 expression. 
 
In SH-SY5Y neuronal cells and primary cortical neurons, sodium butyrate 
prevented olanzapine’s deleterious effects on neurite length, neurite morphology, 
and spine density. Our results are supported by previous in vitro and in vivo study 
in which sodium butyrate promotes the neurite outgrowth. For example, it was 
reported that sodium butyrate promoted the neurite outgrowth and differentiation 
in PC12 cells derived from a pheochromocytoma of the rat adrenal medulla 
(Uittenbogaard et al., 2018, Suzuki-Mizushima et al., 2002). Moreover, chronic 
treatment of sodium butyrate significantly increased spine density in the 
hippocampal region of mice (Takuma et al., 2014). Moreover, the butyrate 
administration enhanced the number of tertiary dendrites of neurons in the brain 
region of the dentate gyrus in mice (Yoo et al., 2011). Previous animal and human 
studies reported that antipsychotics induced the loss in the cortical grey matter 
volume and reduced the number of the synaptic spine in cortical neurons (Vita et 
al., 2015, Ibi et al., 2017, Koini et al., 2018). The loss of synaptic spine attribute to 
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cognitive decline in antipsychotic treated patients (Taoufik et al., 2018, Husa et al., 
2014). Our findings in neurons showed that sodium butyrate improved the 
impairment of synaptogenesis induced by olanzapine, suggesting that sodium 
butyrate may prevent antipsychotics-induce cognitive deficits. In addition, sodium 
butyrate supplementation has been safely used in a clinical trial in obese individuals 
(Cleophas et al., 2019). Therefore, sodium butyrate may have the potential for 
clinical use to prevent antipsychotics-induced deficits in synaptogenesis and 
cognition.  
 
Previously, the long-term treatment of sodium butyrate counteracted with the 
decreased BDNF expression in the hippocampus of mice induced by chronic 
restraint stress (Han et al., 2014). Here, we found that sodium butyrate increased 
the lower BDNF expression induced by olanzapine in neurons. It is known that 
BDNF expression can be suppressed by HDAC2 due to the deacetylation of histone 
3 or 4 near the BDNF promoter (Guan et al., 2009). We found that olanzapine 
increased HDAC2 protein levels, which may be involved in the inhibition of BDNF 
expression. In the present study, sodium butyrate did not inhibit the increased 
HDAC2 protein level induced by olanzapine. However, the enzyme activity assay 
showed that sodium butyrate inhibited the deacetylase activity of both the 
recombinant HDAC2 and SH-SY5Y cells-derived HDAC2 protein. Therefore, 
sodium butyrate in the amelioration of decreased BDNF expression induced by 
olanzapine may be due to its effect on the inhibition of HDAC2 enzyme activity, 
but not HDAC2 protein level. Furthermore, HDAC2 inhibition has been shown to 
rescue impaired synaptogenesis and cognitive deficits. For example, the significant 
increase in spine density, synapse number, and synaptic plasticity was observed in 
the hippocampus of HDAC2 knockout mice (Guan et al., 2009). Also, the  
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HDAC2-deficient mice showed improved learning behaviors and working memory 
compared with the wild type mice. In this study, we found that sodium butyrate 
servers as an HDAC2 inhibitor in the neurons, which may contribute to the 
amelioration of neurite lesions induced by olanzapine.  
 
Our results demonstrated that sodium butyrate at 10μM did not impact the oxidative 
stress in SH-SY5Y neuronal cells. However, previous researches show the dual 
effect of sodium butyrate on oxidative stress. For example, in NRK-52E cells, a rat 
kidney proximal tubular epithelial cell line, the sodium butyrate (0.1mM ~ 1mM) 
increased the level of superoxide dismutase (enzyme against oxidative stress) to 
prevent the oxidative stress induced by high glucose (Du et al., 2020). Besides, 
when HepG2 cells (liver cancer cells) were exposed to 800μM hydrogen peroxide, 
the pre-treatment of sodium butyrate (0.2mM ~ 0.4mM) relieved the ROS 
accumulation via the enhancement of antioxidants (Xing et al., 2016). Furthermore, 
higher doses of sodium butyrate at 4mM induced ROS production in 
hepatocarcinoma cells (Pant et al., 2017b, Pant et al., 2017a). These findings 
suggest that the effect of sodium butyrate on oxidative stress may depend on the 
concentration of sodium butyrate and cell types.  
 
Oxidative stress inhibits the Sirt1 expression and activity; also, the overexpression 
of Sirt1 induces the production of antioxidants (Yeung et al., 2004, He et al., 2019, 
Salminen et al., 2013). In the present study, sodium butyrate at 10μM did not alter 
the Sirt1 level in the SH-SY5Y neuronal cells. This finding is consistent with the 
previous research in which sodium butyrate at 100μM did not affect the gene 
expression of Sirt1 in the lymphoblastoid cells (Rose et al., 2018). However, it is 
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found that higher doses of sodium butyrate affected the Sirt1 level. For example, 
Rose’s team found that sodium butyrate at 1mM increased Sirt1 expression in the 
lymphoblastoid cells. However, sodium butyrate (more than 0.5mM) inhibited the 
Sirt1 expression in lymphoma cells (Das et al., 2015). These findings indicate that 
the sodium butyrate may affect Sirt1 expression at higher doses, but no effects at 
lower doses. In the present study, pre-treatment of sodium butyrate at 10μM did not 
counteract the decreased Sirt1 expression induced by olanzapine along with 
oxidative stress. These findings suggest that the effect of sodium butyrate at higher 
doses to prevent the decreased Sirt1 expression and oxidative stress induced by 
olanzapine requires further examination.  
 
It is confirmed that the butyrate exerts anti-inflammation properties via inhibition 
of NF-κB activation (Hamer et al., 2008, Segain et al., 2000). Also, the similar 
effect was reported that higher doses of sodium butyrate (more than 0.1mM) 
suppressed the phosphorylation of IκBα (NF-κB inhibitor) in colon carcinoma cells, 
inducing inhibition of NF-κB signaling pathway (Lee et al., 2017). In the present 
study, activation of the NF-κB signaling pathway cannot be suppressed by sodium 
butyrate in neurons, which may be due to the lower concentration of sodium 
butyrate and different cell types. The activation of the NF-κB signaling pathway is 
regulated by oxidative stress and Sirt1 inhibition (Canty et al., 1999, Takada et al., 
2003, Kauppinen et al., 2013, Yeung et al., 2004). Therefore, sodium butyrate 
cannot prevent the activation of the NF-κB signaling pathway may be due to 





Our results suggest that sodium butyrate can serve as an HDAC2 inhibitor in a  
dose-dependent manner ranged from 1µM to 10mM. It is consistent with findings 
of previous studies that the half-inhibitory concentration (IC50) of sodium butyrate 
against recombinant HDAC2 is at the low micromolar ranges (Bradner et al., 2010, 
Kilgore et al., 2010, Vogelauer et al., 2012). Moreover, our results demonstrated 
that 10μM sodium butyrate significantly inhibited enzyme deacetylase activity of 
HDAC2 but not the protein level of HDAC2 in SH-SY5Y cells. However, it was 
reported that sodium butyrate at 1mM inhibited the higher HDAC2 protein level 
and enzyme activity induced by high glucose in kidney epithelial-like cells (Du et 
al., 2020). These results suggest that sodium butyrate may only serve as an inhibitor 
of HDAC2 deacetylase activity at a lower dose, but can suppress the protein level 
at the higher dosage.  
 
Conclusion 
Our results showed that the sodium butyrate, served as an HDAC2 enzyme inhibitor, 
improved the BDNF expression, and prevented olanzapine-induced neuronal 
lesions, including shorter neurite outgrowth and decreased spine density in 
neuroblastoma cells and primary cortical neurons. Sodium butyrate at 10uM did 
not affect the oxidative stress, lower Sirt1 expression, activation of NF-κB signaling 
pathway, and overexpression of HDAC2 protein level induced by olanzapine. 
Therefore, the mechanism of sodium butyrate’s neuroprotection effect on the 
prevention of side effects induced by olanzapine was considered as the inhibition 
of the enzyme activity of HDAC2 and enhancement of the expression of the 





Overall discussion and conclusion 
 
Summary of key findings 
 
The present study demonstrated that olanzapine inhibited neurite outgrowth in 
neuroblastoma cells, and shortened dendritic length and decreased spine density in 
the cultured primary cortical neurons (Table 4-1). The treatment of olanzapine 
induced cellular and mitochondrial oxidative stress with lower expression of Sirt1. 
Furthermore, olanzapine activated the NF-κB signaling pathway (overexpression 
of p65 and phosphorylated p65) to upregulate the HDAC2 protein level. The mRNA 
level and protein level of the neurotrophic factor, BDNF, was significantly 
decreased in response to olanzapine in neurons. Therefore, olanzapine-induced 
ROS/Sirt1-NF-κB-HDAC2 may contribute to the BDNF deficit and neurite lesions. 
Importantly, sodium butyrate, as an HDAC2 inhibitor, ameliorated neuronal lesions 
(decreased neurite outgrowth and spine density) and decreased BDNF expression 
induced by olanzapine. However, sodium butyrate did not affect the redox state, 
Sirt1 expression, NF-κB signaling pathway, and HDAC2 protein level. These 
findings suggest that sodium butyrate prevents olanzapine-induced neuronal 
lesions is mainly due to the inhibition of HDAC2 enzyme activity, thereby 
increasing BDNF expression in neurons, rather than targeting the upstream 




Previous clinical studies reported that the lifelong medication of antipsychotic 
drugs is associated with cognitive deficits in schizophrenia (Husa et al., 2014). In 




Parameters                                                                Treatments  Butyrate Olanzapine Butyrate/Olanzapine 
SH-SY5Y cells 
Morphology Neurite outgrowth N.S. ↓*** ↑## 
Oxidative stress 
Cellular ROS level N.S. ↑* ↑* 
Mitochondrial ROS level N.S. ↑* ↑** 
Sirt1 protein level Sirt1 N.S. ↓* ↓* 
NF-κB signaling pathway 
P65 N.S. ↑* ↑* 
P-p65 N/A ↑* N/A 
P50 N.S. N.S. N.S. 
HDAC2 
HDAC2 expression N.S. ↑* ↑* 
HDAC2 deacetylase activity ↓* N/A N/A 
Protein level related to synaptogenesis BDNF  N.S. ↓* ↑# 
Cortical neurons 
Morphology 
Dendritic length N.S. ↓*** ↑## 
Dendritic spine density ↑** ↓** ↑### 
mRNA level related to synaptogenesis 
BDNF N.S. ↓** ↑## 
MAP2 N.S. N.S. N.S. 
Synaptophysin N.S. N.S. N.S. 
PSD95 N.S. N.S. N.S. 
***p < 0.001, **p < 0.01, *p < 0.05, versus the control group; ###p < 0.001, ##p < 0.01, #p < 0.05, versus the olanzapine group; N.S., no significance; N/A, experiments not 
been developed.  




induced impairments in spatial memory capacity. The present study demonstrated 
that olanzapine directly caused the impairment in neurite outgrowth in SH-SY5Y 
cells (Figure 2-1) as well as the decreased total dendritic length and dendritic 
spine density in the cortical neuron (Figure 3-2). Consistently, the in vitro or in 
vivo studies confirmed that some other antipsychotic drugs induce neuronal 
lesions. For example, haloperidol induced neurite deficits both in SH-SHY5Y 
cell and cortical neurons (Hu et al., 2018). Also, the mice with the chronic 
administration of clozapine showed the impairment in mature spine density (Ibi 
et al., 2017). Therefore, it suggests that the impairment in neurogenesis and 
synaptogenesis induced by antipsychotics administration may contribute to the 
cognitive deficits (Huang and Song, 2019). Importantly, in the present study, 
sodium butyrate prevented olanzapine-induced neuronal lesions in SH-SY5Y 
cells and cortical neurons (Figure 3-1, 3-2). Consistently, the sodium butyrate 
was proved that it promoted the neurogenesis in hippocampal neurons,  
PC12-ND6 pheochromocytoma cells and dentate gyrus of mice (Yoo et al., 2011, 
Uittenbogaard et al., 2018). Besides, the neuroprotection effect, as improvements 
in synaptogenesis and cognition, of sodium butyrate has been certified in animal 
models of Alzheimer's disease (Fischer et al., 2007). Furthermore, oral 
administration of sodium butyrate has been applied in the clinical trial for  
anti-inflammatory effects in humans with obesity (Cleophas et al., 2019). 
Therefore, the sodium butyrate supplementation could be a novel treatment to 





The present study showed that olanzapine elevated the ROS level both in the 
intracellular level and mitochondrial level in the neurons (Figure 2-2). It was 
further demonstrated that oxidative stress induced by olanzapine impaired 
mitochondria, and stimulated autophagic clearance of dysfunctional 
mitochondria in SH-SY5Y cells (Vucicevic et al., 2014). In the animal study, the 
administration of antipsychotic drugs, such as olanzapine, clozapine, and 
haloperidol, resulted in higher oxidants and lower antioxidants in rats (Bilgic et 
al., 2017, Schröder et al., 2005). Oxidative stress induces deficits in 
synaptogenesis and cognitive function (Liu et al., 2003). Therefore,  
olanzapine-induced oxidative stress may contribute to mitochondria dysfunction, 
the impairment of synaptogenesis, and cognition deficits. The Sirt1 is important 
for synaptogenesis, while the inhibition of Sirt1 leads to the deficits in 
synaptogenesis of neurons and impairments in cognitive function in mice 
(Hisahara et al., 2008, Guo et al., 2011, Gao et al., 2010). In the present study, 
the Sirt1 level was decreased in the neurons after the treatment of olanzapine.  
Previous research showed that there is an interaction between oxidative stress and 
Sirt1 (Alcendor et al., 2007). Therefore, the crosstalk between oxidative stress 
and Sirt1 alteration induced by olanzapine may contribute to neuronal deficits.  
 
However, the present study showed that the treatment of sodium butyrate at 
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10μM did not inhibit the oxidative stress and prevent the decreased Sirt1 
expression induced by olanzapine (Figure 3-5). Previously, it has been reported 
that the dual effect of sodium butyrate as inhibition or stimulation of oxidative 
stress. For example, 0.5mM and 1mM sodium butyrate decreased ROS level and 
increased antioxidant enzyme level in NRK-52E cells (a rat renal proximal 
tubular cell line) (Du et al., 2020). sodium butyrate at 0.2~0.4mM showed an 
anti-oxidative stress effect in HepG2 cells (liver carcinoma cells) (Xing et al., 
2016). However, the higher dosage of sodium butyrate induced ROS 
accumulation, as 4mM and 5mM sodium butyrate stimulated ROS accumulation 
in Uuh7 hepatic cancer cells (Pant et al., 2017a, Pant et al., 2017b). Also, it 
demonstrated that higher dosages of sodium butyrate (over 0.5mM) inhibited the 
Sirt1 protein expression in 2D10 cells (a latently infected Jurkat T-cell line) (Das 
et al., 2015). Therefore, sodium butyrate regulates ROS production and Sirt1 
expression in a dose-dependent manner. Overall, it suggests that neuroprotective 
effects of sodium butyrate at low dose in neurons does not depend on the 
amelioration of oxidative stress and downregulated Sirt1 expression induced by 
olanzapine. 
 
It has been demonstrated that oxidative stress and downregulated Sirt1 result in 
the activation of the NF-κB signaling pathway (Takada et al., 2003, Kauppinen 
et al., 2013). The present study showed that olanzapine led to the overexpression 
of p65 and phosphorylated p65 in SH-SY5Y neurons (Figure 2-3). This finding 
in neurons was supported by an animal study, in which olanzapine induced 
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stimulation of the NF-κB signaling pathway in the hypothalamus of rats (He et 
al., 2019). The present study also demonstrated the HDAC2 was downstream of 
NF-κB signaling pathway in neurons, since the expression of HDAC2 was 
increased in SH-SY5Y cells transfected with p65 vectors (Figure 2-4). Moreover, 
it was found that olanzapine caused overexpression of HDAC2 in SH-SY5Y cells. 
Therefore, these findings suggest that the phosphorylation of p65 induced by 
olanzapine could promote the translocation of NF-κB to upregulate the HDAC2 
transcription. It is reported that HDAC2 can bind with histones near BDNF 
promoters, which results in the inhibition of BDNF expression (Guan et al., 2009). 
The present study found that olanzapine lowered the mRNA level of BDNF in 
cortical neurons (Figure 3-3) and decreased the protein level of BDNF in  
SH-SY5Y cells (Figure 2-5). These findings indicate that the mechanism of the 
deficit of neurotrophic factor, BDNF, induced by olanzapine is via the activation 
of the NF-κB-HDAC2 pathway (Figure 4-1). 
Figure 4-1 Proposed mechanism of sodium butyrate protect the neuron from lesions caused 
by olanzapine. Olanzapine induces oxidative stress with downregulation of Sirt1 protein, which 
results in the activation of NF-κB signaling pathway. The translocated NF-κB leads to the 
upregulation of HDAC2, which blocks the BDNF expression. Therefore, the neurite outgrowth 
and dendritic spine density is decreased. Sodium butyrate may inhibit the deacetylase activity of 
HDAC2 to protect the neuron from the damage induced by olanzapine. 
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While, in the present study, sodium butyrate at a low dose (10μM) did not inhibit 
the activation of the NF-κB signaling pathway (Figure 3-6) and overexpression 
of HDAC2 induced by olanzapine in the neuron. However, it has been reported 
that higher dosages of sodium butyrate (0.1 and 0.5mM) blocked the activation 
of NF-κB signaling pathway in colon carcinoma cells (Lee et al., 2017), and 
sodium butyrate (1mM) inhibited higher expression of HDAC2 induced by 
glucose in kidney epithelial cells (Du et al., 2020). This suggests that the 
treatment of sodium butyrate affects the NF-κB pathway and HDAC2 protein 
level in a dose-dependent manner. Importantly, the present study demonstrated 
that the deacetylase activity of HDAC2 was inhibited by sodium butyrate at the 
low micromolar range in neurons (Figure 3-4). Therefore, the sodium butyrate at 
low dose in inhibition of deacetylase activity of HDAC2 may contribute to the 
enhancement of BDNF expression and improvement of neuronal damages 
induced by olanzapine. Overall, these findings suggest that inhibition of HDAC2 
enzyme activity and upregulation of BDNF could be potential targets to prevent 
neuronal lesions induced by antipsychotic drugs, while sodium butyrate could be 
a potential compound combined with antipsychotic drugs to encounter cognitive 
impairments for schipzophrenic patients.  
 
Limitations and recommendations for future study 
 
The present study suggests that sodium butyrate protect the neuron via inhibition 
of HDAC2 deacetylase activity. However, sodium butyrate is not the specific 
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HDAC2 inhibitor, HDAC2 shRNA should be used to confirm the specific role of 
HDAC2 in the neuroprotective effect of sodium butyrate.  
 
Although a study showed that HDAC2 binds to the promoter of BDNF (Guan et 
al., 2009), the future experiment should include ChIP-assay to examine whether 
olanzapine directly affects the binding between HDAC2 and the BDNF promoter. 
 
The decreased spine density was shown in primary cortical neurons after 
treatment with olanzapine, while the sodium butyrate ameliorated that effect. 
Since mature spines, such as mushroom-shaped spines, have an important role in 
the strengthening of the synapse, it should be further investigated that whether 
olanzapine or sodium butyrate alter the density of the mushroom-shaped spines 
by using high-resolution microscopy. 
 
The present study was performed in vitro by using SH-SY5Y cells and primary 
cortical neurons to examine the neurite outgrowth and synaptogenesis. The 
results should be further confirmed in other neuroblastoma cell lines and animal 
models. The cognitive index should be evaluated by behavior tests, such as 
Morris water maze, Y maze, novel object recognition tests in rodents after 
administration of olanzapine or sodium butyrate.  
 




Cognitive deficits in schizophrenic patients are associated with the chronic 
administration of antipsychotic drugs. This thesis demonstrated that olanzapine 
induced reduction of neurite outgrowth and spine density, which may contribute 
to cognitive deficits in clinical usage. The underlying mechanism is suggested 
that olanzapine induces oxidative stress and declines Sirt1 expression, thereby 
activation of the NF-κB signaling pathway, overexpression of HDAC2, and 
inhibition of the BDNF transcription. Importantly, the sodium butyrate, as the 
HDAC2 inhibitor, ameliorated the neuronal lesion and BDNF deficit induced by 
olanzapine. Overall, this thesis provides evidence that olanzapine induces 
neuronal lesions, while sodium butyrate can encounter antipsychotics-induced 
adverse effects. These findings suggest that the supplementation of sodium 
butyrate could serve as a potential novel therapeutic for clinical use to improve 













LIST OF REFERENCES 
 
ALCENDOR, R. R., GAO, S., ZHAI, P., ZABLOCKI, D., HOLLE, E., YU, X., TIAN, B., WAGNER, 
T., VATNER, S. F. & SADOSHIMA, J. 2007. Sirt1 Regulates Aging and Resistance to Oxidative 
Stress in the Heart. Circulation Research, 100, 1512-1521. 
ALLANI, P. K., SUM, T., BHANSALI, S. G., MUKHERJEE, S. K. & SONEE, M. 2004. A comparative 
study of the effect of oxidative stress on the cytoskeleton in human cortical neurons. Toxicology 
and Applied Pharmacology, 196, 29-36. 
AMAT, R., SOLANES, G., GIRALT, M. & VILLARROYA, F. 2007. SIRT1 is involved in 
glucocorticoid-mediated control of uncoupling protein-3 gene transcription. J Biol Chem, 282, 
34066-76. 
ASENJO‐LOBOS, C., FONSECA, C., LEUCHT, S., ARANCIBIA, M. & CORTÉS‐JOFRÉ, M. 2018. 
Clozapine versus olanzapine for people with schizophrenia. Cochrane Database of Systematic 
Reviews. 
ASHABI, G., AHMADIANI, A., ABDI, A., ABRAKI, S. B. & KHODAGHOLI, F. 2013. Time course 
study of Aβ formation and neurite outgrowth disruption in differentiated human neuroblastoma 
cells exposed to H2O2: Protective role of autophagy. Toxicology in Vitro, 27, 1780-1788. 
ASHCROFT, D. M., FRISCHER, M., LOCKETT, J. & CHAPMAN, S. R. 2002. Variations in prescribing 
atypical antipsychotic drugs in primary care: cross-sectional study. Pharmacoepidemiology and 
77 
 
Drug Safety, 11, 285-289. 
AVILA-COSTA, M. A. R., COLı́N-BARENQUE, L., FORTOUL, T. I., MACHADO-SALAS, J. P., 
ESPINOSA-VILLANUEVA, J., RUGERIO-VARGAS, C. & RIVAS-ARANCIBIA, S. 1999. 
Memory deterioration in an oxidative stress model and its correlation with cytological changes 
on rat hippocampus CA1. Neuroscience Letters, 270, 107-109. 
BAI, O., CHLAN‐FOURNEY, J., BOWEN, R., KEEGAN, D. & LI, X. M. 2003. Expression of brain‐
derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs. 
Journal of neuroscience research, 71, 127-131. 
BAKER, J. R., VUPPUSETTY, C., COLLEY, T., PAPAIOANNOU, A. I., FENWICK, P., DONNELLY, 
L., ITO, K. & BARNES, P. J. 2016. Oxidative stress dependent microRNA-34a activation via 
PI3Kα reduces the expression of sirtuin-1 and sirtuin-6 in epithelial cells. Scientific Reports, 6, 
35871. 
BALLARD, D. W., DIXON, E. P., PEFFER, N. J., BOGERD, H., DOERRE, S., STEIN, B. & GREENE, 
W. C. 1992. The 65-kDa subunit of human NF-kappa B functions as a potent transcriptional 
activator and a target for v-Rel-mediated repression. Proc Natl Acad Sci U S A, 89, 1875-9. 
BEASLEY, C. M., JR., TOLLEFSON, G., TRAN, P., SATTERLEE, W., SANGER, T. & HAMILTON, 
S. 1996. Olanzapine versus placebo and haloperidol: acute phase results of the North American 
double-blind olanzapine trial. Neuropsychopharmacology, 14, 111-23. 
BELLON, A. 2007. New genes associated with schizophrenia in neurite formation: a review of cell 
culture experiments. Molecular Psychiatry, 12, 620. 
78 
 
BENITO, E., URBANKE, H., RAMACHANDRAN, B., BARTH, J., HALDER, R., AWASTHI, A., 
JAIN, G., CAPECE, V., BURKHARDT, S., NAVARRO-SALA, M., NAGARAJAN, S., 
SCHÜTZ, A.-L., JOHNSEN, S. A., BONN, S., LÜHRMANN, R., DEAN, C. & FISCHER, A. 
2015. HDAC inhibitor-dependent transcriptome and memory reinstatement in cognitive decline 
models. The Journal of clinical investigation, 125, 3572-3584. 
BERRY, K. P. & NEDIVI, E. 2017. Spine Dynamics: Are They All the Same? Neuron, 96, 43-55. 
BILGIC, S., TASTEMIR KORKMAZ, D., AZIRAK, S., GUVENC, A. N., KOCAMAN, N. & OZER, 
M. K. 2017. The protective effect of thymoquinone over olanzapine-induced side effects in liver, 
and metabolic side effects. Bratisl Lek Listy, 118, 618-625. 
BJERLING, P., SILVERSTEIN, R. A., THON, G., CAUDY, A., GREWAL, S. & EKWALL, K. 2002. 
Functional divergence between histone deacetylases in fission yeast by distinct cellular 
localization and in vivo specificity. Molecular and cellular biology, 22, 2170-2181. 
BORDONE, L., MOTTA, M. C., PICARD, F., ROBINSON, A., JHALA, U. S., APFELD, J., 
MCDONAGH, T., LEMIEUX, M., MCBURNEY, M., SZILVASI, A., EASLON, E. J., LIN, S.-
J. & GUARENTE, L. 2006. Sirt1 regulates insulin secretion by repressing UCP2 in pancreatic 
beta cells. PLoS biology, 4, e31-e31. 
BOŠKOVIĆ, M., VOVK, T., KORES PLESNIČAR, B. & GRABNAR, I. 2011. Oxidative stress in 
schizophrenia. Current neuropharmacology, 9, 301-312. 
BOURNE, J. & HARRIS, K. M. 2007. Do thin spines learn to be mushroom spines that remember? 
Current Opinion in Neurobiology, 17, 381-386. 
79 
 
BRADNER, J. E., MAK, R., TANGUTURI, S. K., MAZITSCHEK, R., HAGGARTY, S. J., ROSS, K., 
CHANG, C. Y., BOSCO, J., WEST, N., MORSE, E., LIN, K., SHEN, J. P., KWIATKOWSKI, 
N. P., GHELDOF, N., DEKKER, J., DEANGELO, D. J., CARR, S. A., SCHREIBER, S. L., 
GOLUB, T. R. & EBERT, B. L. 2010. Chemical genetic strategy identifies histone deacetylase 
1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease. Proc Natl Acad Sci U S A, 
107, 12617-22. 
BRAND, M. D. & ESTEVES, T. C. 2005. Physiological functions of the mitochondrial uncoupling 
proteins UCP2 and UCP3. Cell Metabolism, 2, 85-93. 
BYMASTER, F. P., CARTER, P. A., PETERS, S. C., ZHANG, W., WARD, J. S., MITCH, C. H., 
CALLIGARO, D. O., WHITESITT, C. A., DELAPP, N., SHANNON, H. E., RIMVALL, K., 
JEPPESEN, L., SHEARDOWN, M. J., FINK-JENSEN, A. & SAUERBERG, P. 1998. 
Xanomeline compared to other muscarinic agents on stimulation of phosphoinositide hydrolysis 
in vivo and other cholinomimetic effects. Brain Res, 795, 179-90. 
BYMASTER, F. P., RASMUSSEN, K., CALLIGARO, D. O., NELSON, D. L., DELAPP, N. W., WONG, 
D. T. & MOORE, N. A. 1997. In vitro and in vivo biochemistry of olanzapine: a novel, atypical 
antipsychotic drug. J Clin Psychiatry, 58 Suppl 10, 28-36. 
CAITO, S., RAJENDRASOZHAN, S., COOK, S., CHUNG, S., YAO, H., FRIEDMAN, A. E., 
BROOKES, P. S. & RAHMAN, I. 2010. SIRT1 is a redox-sensitive deacetylase that is post-
translationally modified by oxidants and carbonyl stress. FASEB journal : official publication 
of the Federation of American Societies for Experimental Biology, 24, 3145-3159. 
80 
 
CANTY, T. G., JR., BOYLE, E. M., JR., FARR, A., MORGAN, E. N., VERRIER, E. D. & POHLMAN, 
T. H. 1999. Oxidative stress induces NF-kappaB nuclear translocation without degradation of 
IkappaBalpha. Circulation, 100, Ii361-4. 
CHEN, Z., SHENTU, T. P., WEN, L., JOHNSON, D. & SHYY, J. 2013. Regulation of SIRT1 by 
Oxidative Stress-Responsive miRNAs and A Systematic Approach to Identify Its Role in the 
Endothelium. Antioxidants & redox signaling. 
CHEUNG, Y.-T., LAU, W. K.-W., YU, M.-S., LAI, C. S.-W., YEUNG, S.-C., SO, K.-F. & CHANG, R. 
C.-C. 2009. Effects of all-trans-retinoic acid on human SH-SY5Y neuroblastoma as in vitro 
model in neurotoxicity research. NeuroToxicology, 30, 127-135. 
CLEOPHAS, M. C. P., RATTER, J. M., BEKKERING, S., QUINTIN, J., SCHRAA, K., STROES, E. S., 
NETEA, M. G. & JOOSTEN, L. A. B. 2019. Effects of oral butyrate supplementation on 
inflammatory potential of circulating peripheral blood mononuclear cells in healthy and obese 
males. Scientific reports, 9, 775-775. 
CODOCEDO, J. F., ALLARD, C., GODOY, J. A., VARELA-NALLAR, L. & INESTROSA, N. C. 2012. 
SIRT1 regulates dendritic development in hippocampal neurons. PloS one, 7, e47073-e47073. 
COVINGTON, H. E., 3RD, MAZE, I., LAPLANT, Q. C., VIALOU, V. F., OHNISHI, Y. N., BERTON, 
O., FASS, D. M., RENTHAL, W., RUSH, A. J., 3RD, WU, E. Y., GHOSE, S., KRISHNAN, V., 
RUSSO, S. J., TAMMINGA, C., HAGGARTY, S. J. & NESTLER, E. J. 2009. Antidepressant 
actions of histone deacetylase inhibitors. The Journal of neuroscience : the official journal of 
the Society for Neuroscience, 29, 11451-11460. 
81 
 
DALILE, B., VAN OUDENHOVE, L., VERVLIET, B. & VERBEKE, K. 2019. The role of short-chain 
fatty acids in microbiota–gut–brain communication. Nature Reviews Gastroenterology & 
Hepatology, 16, 461-478. 
DAS, B., DOBROWOLSKI, C., SHAHIR, A.-M., FENG, Z., YU, X., SHA, J., BISSADA, N. F., 
WEINBERG, A., KARN, J. & YE, F. 2015. Short chain fatty acids potently induce latent HIV-
1 in T-cells by activating P-TEFb and multiple histone modifications. Virology, 474, 65-81. 
DAVIE, J. R. 2003. Inhibition of Histone Deacetylase Activity by Butyrate. The Journal of Nutrition, 
133, 2485S-2493S. 
DAWE, G. S., HWANG, E. H. & TAN, C. H. 2009. Pathophysiology and animal models of schizophrenia. 
Ann Acad Med Singapore, 38, 425-426. 
DE LA FUENTE REVENGA, M., IBI, D., SAUNDERS, J. M., CUDDY, T., IJAZ, M. K., TONEATTI, 
R., KURITA, M., HOLLOWAY, T., SHEN, L., SETO, J., DOZMOROV, M. G. & GONZALEZ-
MAESO, J. 2018. HDAC2-dependent Antipsychotic-like Effects of Chronic Treatment with the 
HDAC Inhibitor SAHA in Mice. Neuroscience, 388, 102-117. 
DE RUIJTER, A. J., VAN GENNIP, A. H., CARON, H. N., STEPHAN, K. & VAN KUILENBURG, A. 
B. 2003. Histone deacetylases (HDACs): characterization of the classical HDAC family. 
Biochemical Journal, 370, 737-749. 
DEHMELT, L. & HALPAIN, S. 2004. The MAP2/Tau family of microtubule-associated proteins. 
Genome Biology, 6, 204. 
82 
 
DELCUVE, G. P., KHAN, D. H. & DAVIE, J. R. 2012. Roles of histone deacetylases in epigenetic 
regulation: emerging paradigms from studies with inhibitors. Clinical Epigenetics, 4, 5. 
DOKMANOVIC, M., CLARKE, C. & MARKS, P. A. 2007. Histone deacetylase inhibitors: overview 
and perspectives. Mol Cancer Res, 5, 981-9. 
DOLCET, X., LLOBET, D., PALLARES, J. & MATIAS-GUIU, X. 2005. NF-kB in development and 
progression of human cancer. Virchows Archiv, 446, 475-482. 
DONADELLI, R., ABBATE, M., ZANCHI, C., CORNA, D., TOMASONI, S., BENIGNI, A., 
REMUZZI, G. & ZOJA, C. 2000. Protein traffic activates NF-kB gene signaling and promotes 
MCP-1–dependent interstitial inflammation. American Journal of Kidney Diseases, 36, 1226-
1241. 
DU, Y., TANG, G. & YUAN, W. 2020. Suppression of HDAC2 by sodium butyrate alleviates apoptosis 
of kidney cells in db/db mice and HG‑induced NRK‑52E cells. Int J Mol Med, 45, 210-222. 
DUNAEVSKY, A., TASHIRO, A., MAJEWSKA, A., MASON, C. & YUSTE, R. 1999. Developmental 
regulation of spine motility in the mammalian central nervous system. Proceedings of the 
National Academy of Sciences of the United States of America, 96, 13438-13443. 
DWORK, A. J., MANCEVSKI, B. & ROSOKLIJA, G. 2007. White matter and cognitive function in 
schizophrenia. Int J Neuropsychopharmacol, 10, 513-36. 
ELIE, D., POIRIER, M., CHIANETTA, J., DURAND, M., GREGOIRE, C. & GRIGNON, S. 2010. 
Cognitive effects of antipsychotic dosage and polypharmacy: a study with the BACS in patients 
83 
 
with schizophrenia and schizoaffective disorder. J Psychopharmacol, 24, 1037-44. 
FANG, X., CHEN, Y., WANG, Y., REN, J. & ZHANG, C. 2019. Depressive symptoms in schizophrenia 
patients: A possible relationship between SIRT1 and BDNF. Progress in Neuro-
Psychopharmacology and Biological Psychiatry, 95, 109673. 
FEHSEL, K., LOEFFLER, S., KRIEGER, K., HENNING, U., AGELINK, M., KOLB-BACHOFEN, V. 
& KLIMKE, A. 2005. Clozapine induces oxidative stress and proapoptotic gene expression in 
neutrophils of schizophrenic patients. J Clin Psychopharmacol, 25, 419-26. 
FELLOWS, R., DENIZOT, J., STELLATO, C., CUOMO, A., JAIN, P., STOYANOVA, E., BALÁZSI, 
S., HAJNÁDY, Z., LIEBERT, A., KAZAKEVYCH, J., BLACKBURN, H., CORRÊA, R. O., 
FACHI, J. L., SATO, F. T., RIBEIRO, W. R., FERREIRA, C. M., PERÉE, H., SPAGNUOLO, 
M., MATTIUZ, R., MATOLCSI, C., GUEDES, J., CLARK, J., VELDHOEN, M., BONALDI, 
T., VINOLO, M. A. R. & VARGA-WEISZ, P. 2018. Microbiota derived short chain fatty acids 
promote histone crotonylation in the colon through histone deacetylases. Nature 
Communications, 9, 105. 
FISCHER, A., SANANBENESI, F., WANG, X., DOBBIN, M. & TSAI, L.-H. 2007. Recovery of 
learning and memory is associated with chromatin remodelling. Nature, 447, 178. 
FORMAN, H. J. & KENNEDY, J. A. 1974. Role of superoxide radical in mitochondrial dehydrogenase 
reactions. Biochem Biophys Res Commun, 60, 1044-50. 
FUKUI, K., USHIKI, K., TAKATSU, H., KOIKE, T. & URANO, S. 2012. Tocotrienols prevent hydrogen 




FUNAKOHI-TAGO, M., SAKATA, T., FUJIWARA, S., SAKAKURA, A., SUGAI, T., TAGO, K. & 
TAMURA, H. 2018. Hydroxytyrosol butyrate inhibits 6-OHDA-induced apoptosis through 
activation of the Nrf2/HO-1 axis in SH-SY5Y cells. European Journal of Pharmacology, 834, 
246-256. 
FUNKE, L., DAKOJI, S. & BREDT, D. S. 2005. MEMBRANE-ASSOCIATED GUANYLATE 
KINASES REGULATE ADHESION AND PLASTICITY AT CELL JUNCTIONS. Annual 
Review of Biochemistry, 74, 219-245. 
GAO, J., WANG, W.-Y., MAO, Y.-W., GRÄFF, J., GUAN, J.-S., PAN, L., MAK, G., KIM, D., SU, S. C. 
& TSAI, L.-H. 2010. A novel pathway regulates memory and plasticity via SIRT1 and miR-134. 
Nature, 466, 1105-1109. 
GAO, Z., ZHANG, J., KHETERPAL, I., KENNEDY, N., DAVIS, R. J. & YE, J. 2011. Sirtuin 1 (SIRT1) 
protein degradation in response to persistent c-Jun N-terminal kinase 1 (JNK1) activation 
contributes to hepatic steatosis in obesity. J Biol Chem, 286, 22227-34. 
GARRAWAY, S. M. & HUIE, J. R. 2016. Spinal Plasticity and Behavior: BDNF-Induced 
Neuromodulation in Uninjured and Injured Spinal Cord. Neural plasticity, 2016, 9857201-
9857201. 
GAUB, P., TEDESCHI, A., PUTTAGUNTA, R., NGUYEN, T., SCHMANDKE, A. & DI GIOVANNI, 
S. 2010. HDAC inhibition promotes neuronal outgrowth and counteracts growth cone collapse 




GHOSHAL, A., ROOK, J. M., DICKERSON, J. W., ROOP, G. N., MORRISON, R. D., JALAN-
SAKRIKAR, N., LAMSAL, A., NOETZEL, M. J., POSLUSNEY, M. S., WOOD, M. R., 
MELANCON, B. J., STAUFFER, S. R., XIANG, Z., DANIELS, J. S., NISWENDER, C. M., 
JONES, C. K., LINDSLEY, C. W. & CONN, P. J. 2016. Potentiation of M1 Muscarinic Receptor 
Reverses Plasticity Deficits and Negative and Cognitive Symptoms in a Schizophrenia Mouse 
Model. Neuropsychopharmacology, 41, 598-610. 
GILBERT, T. M., ZURCHER, N. R., WU, C. J., BHANOT, A., HIGHTOWER, B. G., KIM, M., 
ALBRECHT, D. S., WEY, H. Y., SCHROEDER, F. A., RODRIGUEZ-THOMPSON, A., 
MORIN, T. M., HART, K. L., PELLEGRINI, A. M., RILEY, M. M., WANG, C., 
STUFFLEBEAM, S. M., HAGGARTY, S. J., HOLT, D. J., LOGGIA, M. L., PERLIS, R. H., 
BROWN, H. E., ROFFMAN, J. L. & HOOKER, J. M. 2019. PET neuroimaging reveals histone 
deacetylase dysregulation in schizophrenia. J Clin Invest, 129, 364-372. 
GLAUSIER, J. R. & LEWIS, D. A. 2013. Dendritic spine pathology in schizophrenia. Neuroscience, 251, 
90-107. 
GONZALEZ-LIENCRES, C., TAS, C., BROWN, E. C., ERDIN, S., ONUR, E., CUBUKCOGLU, Z., 
AYDEMIR, O., ESEN-DANACI, A. & BRÜNE, M. 2014. Oxidative stress in schizophrenia: a 
case-control study on the effects on social cognition and neurocognition. BMC psychiatry, 14, 
268-268. 
GOUGH, D. R. & COTTER, T. G. 2011. Hydrogen peroxide: a Jekyll and Hyde signalling molecule. 
86 
 
Cell death & disease, 2, e213-e213. 
GRÄFF, J., JOSEPH, N. F., HORN, M. E., SAMIEI, A., MENG, J., SEO, J., REI, D., BERO, A. W., 
PHAN, T. X., WAGNER, F., HOLSON, E., XU, J., SUN, J., NEVE, R. L., MACH, R. H., 
HAGGARTY, S. J. & TSAI, L.-H. 2014. Epigenetic priming of memory updating during 
reconsolidation to attenuate remote fear memories. Cell, 156, 261-276. 
GRÄFF, J., REI, D., GUAN, J. S., WANG, W. Y., SEO, J., HENNIG, K. M., NIELAND, T. J., FASS, D. 
M., KAO, P. F., KAHN, M., SU, S. C., SAMIEI, A., JOSEPH, N., HAGGARTY, S. J., 
DELALLE, I. & TSAI, L. H. 2012. An epigenetic blockade of cognitive functions in the 
neurodegenerating brain. Nature, 483, 222-6. 
GRILLO, R. W., OTTONI, G. L., LEKE, R., SOUZA, D. O., PORTELA, L. V. & LARA, D. R. 2007. 
Reduced serum BDNF levels in schizophrenic patients on clozapine or typical antipsychotics. 
Journal of Psychiatric Research, 41, 31-35. 
GUAN, J. S., HAGGARTY, S. J., GIACOMETTI, E., DANNENBERG, J. H., JOSEPH, N., GAO, J., 
NIELAND, T. J. F., ZHOU, Y., WANG, X., MAZITSCHEK, R., BRADNER, J. E., DEPINHO, 
R. A., JAENISCH, R. & TSAI, L.-H. 2009. HDAC2 negatively regulates memory formation 
and synaptic plasticity. Nature, 459, 55-60. 
GUDI, V., GAI, L., HERDER, V., TEJEDOR, L. S., KIPP, M., AMOR, S., SÜHS, K.-W., HANSMANN, 
F., BEINEKE, A., BAUMGÄRTNER, W., STANGEL, M. & SKRIPULETZ, T. 2017. 
Synaptophysin Is a Reliable Marker for Axonal Damage. Journal of Neuropathology & 
Experimental Neurology, 76, 109-125. 
87 
 
GUO, W., QIAN, L., ZHANG, J., ZHANG, W., MORRISON, A., HAYES, P., WILSON, S., CHEN, T. 
& ZHAO, J. 2011. Sirt1 overexpression in neurons promotes neurite outgrowth and cell survival 
through inhibition of the mTOR signaling. Journal of neuroscience research, 89, 1723-1736. 
GUTIERREZ, H., O'KEEFFE, G. W., GAVALDÀ, N., GALLAGHER, D. & DAVIES, A. M. 2008. 
Nuclear factor kappa B signaling either stimulates or inhibits neurite growth depending on the 
phosphorylation status of p65/RelA. The Journal of neuroscience : the official journal of the 
Society for Neuroscience, 28, 8246-8256. 
HACIOGLU, G., SENTURK, A., INCE, I. & ALVER, A. 2016. Assessment of oxidative stress 
parameters of brain-derived neurotrophic factor heterozygous mice in acute stress model. 
Iranian journal of basic medical sciences, 19, 388-393. 
HALLIWELL, B. 2001. Role of free radicals in the neurodegenerative diseases: therapeutic implications 
for antioxidant treatment. Drugs Aging, 18, 685-716. 
HAMER, H. M., JONKERS, D., VENEMA, K., VANHOUTVIN, S., TROOST, F. & BRUMMER, R. J. 
2008. The role of butyrate on colonic function. Alimentary pharmacology & therapeutics, 27, 
104-119. 
HAN, A., SUNG, Y.-B., CHUNG, S.-Y. & KWON, M.-S. 2014. Possible additional antidepressant-like 
mechanism of sodium butyrate: Targeting the hippocampus. Neuropharmacology, 81, 292-302. 
HANSON, J. E., DENG, L., HACKOS, D. H., LO, S.-C., LAUFFER, B. E., STEINER, P. & ZHOU, Q. 
2013. Histone Deacetylase 2 Cell Autonomously Suppresses Excitatory and Enhances 




HE, M., HUANG, X. F., GAO, G., ZHOU, T., LI, W., HU, J., CHEN, J., LI, J. & SUN, T. 2019. 
Olanzapine-induced endoplasmic reticulum stress and inflammation in the hypothalamus were 
inhibited by an ER stress inhibitor 4-phenylbutyrate. Psychoneuroendocrinology, 104, 286-299. 
HERSKOVITS, A. Z. & GUARENTE, L. 2014. SIRT1 in neurodevelopment and brain senescence. 
Neuron, 81, 471-83. 
HILGENBERG, L. G. & SMITH, M. A. 2007. Preparation of dissociated mouse cortical neuron cultures. 
J Vis Exp, 562. 
HILL, S. K., BISHOP, J. R., PALUMBO, D. & SWEENEY, J. A. 2010. Effect of second-generation 
antipsychotics on cognition: current issues and future challenges. Expert Review of 
Neurotherapeutics, 10, 43-57. 
HISAHARA, S., CHIBA, S., MATSUMOTO, H., TANNO, M., YAGI, H., SHIMOHAMA, S., SATO, 
M. & HORIO, Y. 2008. Histone deacetylase SIRT1 modulates neuronal differentiation by its 
nuclear translocation. Proceedings of the National Academy of Sciences, 105, 15599-15604. 
HOCKLY, E., RICHON, V. M., WOODMAN, B., SMITH, D. L., ZHOU, X., ROSA, E., SATHASIVAM, 
K., GHAZI-NOORI, S., MAHAL, A., LOWDEN, P. A., STEFFAN, J. S., MARSH, J. L., 
THOMPSON, L. M., LEWIS, C. M., MARKS, P. A. & BATES, G. P. 2003. Suberoylanilide 
hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model 
of Huntington's disease. Proc Natl Acad Sci U S A, 100, 2041-6. 
89 
 
HONG, S., IIZUKA, Y., LEE, T., KIM, C. Y. & SEONG, G. J. 2014. Neuroprotective and neurite 
outgrowth effects of maltol on retinal ganglion cells under oxidative stress. Molecular vision, 
20, 1456-1462. 
HORI, Y. S., KUNO, A., HOSODA, R. & HORIO, Y. 2013. Regulation of FOXOs and p53 by SIRT1 
modulators under oxidative stress. PloS one, 8, e73875-e73875. 
HU, M., ZHENG, P., XIE, Y., BOZ, Z., YU, Y., TANG, R., JONES, A., ZHENG, K. & HUANG, X.-F. 
2018. Propionate protects haloperidol-induced neurite lesions mediated by neuropeptide Y. 
Frontiers in neuroscience, 12, 743. 
HUANG, B., YANG, X.-D., LAMB, A. & CHEN, L.-F. 2010. Posttranslational modifications of NF-
kappaB: another layer of regulation for NF-kappaB signaling pathway. Cellular signalling, 22, 
1282-1290. 
HUANG, X., HAN, M., HUANG, X., ZAVITSANOU, K. & DENG, C. 2006. Olanzapine differentially 
affects 5-HT2Aand2C receptor mRNA expression in the rat brain. Behav Brain Res, 171, 355-
62. 
HUANG, X. F. & SONG, X. 2019. Effects of antipsychotic drugs on neurites relevant to schizophrenia 
treatment. Medicinal research reviews, 39, 386-403. 
HUHN, M., NIKOLAKOPOULOU, A., SCHNEIDER-THOMA, J., KRAUSE, M., SAMARA, M., 
PETER, N., ARNDT, T., BÄCKERS, L., ROTHE, P., CIPRIANI, A., DAVIS, J., SALANTI, G. 
& LEUCHT, S. 2019. Comparative efficacy and tolerability of 32 oral antipsychotics for the 
acute treatment of adults with multi-episode schizophrenia: a systematic review and network 
90 
 
meta-analysis. Lancet, 394, 939-951. 
HULSMANS, M., KEYZER, D. D. & HOLVOET, P. 2011. MicroRNAs regulating oxidative stress and 
inflammation in relation to obesity and atherosclerosis. The FASEB Journal, 25, 2515-2527. 
HUSA, A. P., RANNIKKO, I., MOILANEN, J., HAAPEA, M., MURRAY, G. K., BARNETT, J., JONES, 
P. B., ISOHANNI, M., KOPONEN, H., MIETTUNEN, J. & JÄÄSKELÄINEN, E. 2014. 
Lifetime use of antipsychotic medication and its relation to change of verbal learning and 
memory in midlife schizophrenia — An observational 9-year follow-up study. Schizophrenia 
Research, 158, 134-141. 
HUUSKONEN, J., SUURONEN, T., NUUTINEN, T., KYRYLENKO, S. & SALMINEN, A. 2004. 
Regulation of microglial inflammatory response by sodium butyrate and short-chain fatty acids. 
Br J Pharmacol. 2004 Mar;141(5):874-80. doi: 10.1038/sj.bjp.0705682. Epub 2004 Jan 26. 
IBI, D., DE LA FUENTE REVENGA, M., KEZUNOVIC, N., MUGURUZA, C., SAUNDERS, J. M., 
GAITONDE, S. A., MORENO, J. L., IJAZ, M. K., SANTOSH, V., KOZLENKOV, A., 
HOLLOWAY, T., SETO, J., GARCIA-BEA, A., KURITA, M., MOSLEY, G. E., JIANG, Y., 
CHRISTOFFEL, D. J., CALLADO, L. F., RUSSO, S. J., DRACHEVA, S., LOPEZ-GIMENEZ, 
J. F., GE, Y., ESCALANTE, C. R., MEANA, J. J., AKBARIAN, S., HUNTLEY, G. W. & 
GONZALEZ-MAESO, J. 2017. Antipsychotic-induced Hdac2 transcription via NF-kappaB 
leads to synaptic and cognitive side effects. Nat Neurosci, 20, 1247-1259. 
ITO, K., BARNES, P. J. & ADCOCK, I. M. 2000. Glucocorticoid receptor recruitment of histone 
deacetylase 2 inhibits interleukin-1β-induced histone H4 acetylation on lysines 8 and 12. 
91 
 
Molecular and cellular biology, 20, 6891-6903. 
JAIN, S., BANERJEE, B. D., AHMED, R. S., ARORA, V. K. & MEDIRATTA, P. K. 2013. Possible role 
of oxidative stress and brain derived neurotrophic factor in triazophos induced cognitive 
impairment in rats. Neurochem Res, 38, 2136-47. 
JEONG, H., COHEN, D. E., CUI, L., SUPINSKI, A., SAVAS, J. N., MAZZULLI, J. R., YATES, J. R., 
BORDONE, L., GUARENTE, L. & KRAINC, D. 2012. Sirt1 mediates neuroprotection from 
mutant huntingtin by activation of the TORC1 and CREB transcriptional pathway. Nature 
medicine, 18, 159-165. 
JI, Y., LU, Y., YANG, F., SHEN, W., TANG, T. T.-T., FENG, L., DUAN, S. & LU, B. 2010. Acute and 
gradual increases in BDNF concentration elicit distinct signaling and functions in neurons. 
Nature neuroscience, 13, 302-309. 
JIANG, M., WANG, J., FU, J., DU, L., JEONG, H., WEST, T., XIANG, L., PENG, Q., HOU, Z., CAI, 
H., SEREDENINA, T., ARBEZ, N., ZHU, S., SOMMERS, K., QIAN, J., ZHANG, J., MORI, 
S., YANG, X. W., TAMASHIRO, K. L. K., AJA, S., MORAN, T. H., LUTHI-CARTER, R., 
MARTIN, B., MAUDSLEY, S., MATTSON, M. P., CICHEWICZ, R. H., ROSS, C. A., 
HOLTZMAN, D. M., KRAINC, D. & DUAN, W. 2011. Neuroprotective role of Sirt1 in 
mammalian models of Huntington's disease through activation of multiple Sirt1 targets. Nature 
medicine, 18, 153-158. 
JOHNSTONE, R. W. 2002. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. 
Nature reviews Drug discovery, 1, 287. 
92 
 
KABEL, A. M., OMAR, M. S. & ELMAABOUD, M. A. A. 2016. Amelioration of bleomycin-induced 
lung fibrosis in rats by valproic acid and butyrate: Role of nuclear factor kappa-B, 
proinflammatory cytokines and oxidative stress. International Immunopharmacology, 39, 335-
342. 
KAMATA, H., HONDA, S., MAEDA, S., CHANG, L., HIRATA, H. & KARIN, M. 2005. Reactive 
oxygen species promote TNFalpha-induced death and sustained JNK activation by inhibiting 
MAP kinase phosphatases. Cell, 120, 649-61. 
KAMSLER, A. & SEGAL, M. 2003. Hydrogen Peroxide Modulation of Synaptic Plasticity. The Journal 
of Neuroscience, 23, 269-276. 
KANFI, Y., NAIMAN, S., AMIR, G., PESHTI, V., ZINMAN, G., NAHUM, L., BAR-JOSEPH, Z. & 
COHEN, H. Y. 2012. The sirtuin SIRT6 regulates lifespan in male mice. Nature, 483, 218-221. 
KAPCZINSKI, F., FREY, B. N., ANDREAZZA, A. C., KAUER-SANT'ANNA, M., CUNHA, A. B. & 
POST, R. M. 2008. Increased oxidative stress as a mechanism for decreased BDNF levels in 
acute manic episodes. Braz J Psychiatry, 30, 243-5. 
KASUBUCHI, M., HASEGAWA, S., HIRAMATSU, T., ICHIMURA, A. & KIMURA, I. 2015. Dietary 
gut microbial metabolites, short-chain fatty acids, and host metabolic regulation. Nutrients, 7, 
2839-2849. 
KAUPPINEN, A., SUURONEN, T., OJALA, J., KAARNIRANTA, K. & SALMINEN, A. 2013. 
Antagonistic crosstalk between NF-κB and SIRT1 in the regulation of inflammation and 
metabolic disorders. Cell Signal, 25, 1939-48. 
93 
 
KAWAI, Y., GARDUÑO, L., THEODORE, M., YANG, J. & ARINZE, I. J. 2011. Acetylation-
deacetylation of the transcription factor Nrf2 (nuclear factor erythroid 2-related factor 2) 
regulates its transcriptional activity and nucleocytoplasmic localization. J Biol Chem, 286, 
7629-40. 
KELLNER, Y., GOEDECKE, N., DIERKES, T., THIEME, N., ZAGREBELSKY, M. & KORTE, M. 
2014. The BDNF effects on dendritic spines of mature hippocampal neurons depend on neuronal 
activity. Frontiers in Synaptic Neuroscience, 6. 
KENNEDY, A. J., RAHN, E. J., PAULUKAITIS, B. S., SAVELL, K. E., KORDASIEWICZ, H. B., 
WANG, J., LEWIS, J. W., POSEY, J., STRANGE, S. K., GUZMAN-KARLSSON, M. C., 
PHILLIPS, S. E., DECKER, K., MOTLEY, S. T., SWAYZE, E. E., ECKER, D. J., MICHAEL, 
T. P., DAY, J. J. & SWEATT, J. D. 2016. Tcf4 Regulates Synaptic Plasticity, DNA Methylation, 
and Memory Function. Cell Rep, 16, 2666-2685. 
KHAN, N. A., RAINE, L. B., DROLLETTE, E. S., SCUDDER, M. R., KRAMER, A. F. & HILLMAN, 
C. H. 2015. Dietary fiber is positively associated with cognitive control among prepubertal 
children. The Journal of nutrition, 145, 143-149. 
KILGORE, M., MILLER, C. A., FASS, D. M., HENNIG, K. M., HAGGARTY, S. J., SWEATT, J. D. & 
RUMBAUGH, G. 2010. Inhibitors of Class 1 Histone Deacetylases Reverse Contextual 
Memory Deficits in a Mouse Model of Alzheimer's Disease. Neuropsychopharmacology, 35, 
870-880. 
KIM, D., NGUYEN, M. D., DOBBIN, M. M., FISCHER, A., SANANBENESI, F., RODGERS, J. T., 
94 
 
DELALLE, I., BAUR, J. A., SUI, G., ARMOUR, S. M., PUIGSERVER, P., SINCLAIR, D. A. 
& TSAI, L.-H. 2007. SIRT1 deacetylase protects against neurodegeneration in models for 
Alzheimer's disease and amyotrophic lateral sclerosis. The EMBO journal, 26, 3169-3179. 
KIM, D. S., KWON, J. E., LEE, S. H., KIM, E. K., RYU, J. G., JUNG, K. A., CHOI, J. W., PARK, M. 
J., MOON, Y. M., PARK, S. H., CHO, M. L. & KWOK, S. K. 2018. Attenuation of Rheumatoid 
Inflammation by Sodium Butyrate Through Reciprocal Targeting of HDAC2 in Osteoclasts and 
HDAC8 in T Cells. Front Immunol, 9, 1525. 
KISHI, T., FUKUO, Y., KITAJIMA, T., OKOCHI, T., YAMANOUCHI, Y., KINOSHITA, Y., 
KAWASHIMA, K., INADA, T., KUNUGI, H. & KATO, T. 2011. SIRT1 gene, schizophrenia 
and bipolar disorder in the Japanese population: an association study. Genes, Brain and Behavior, 
10, 257-263. 
KLEIN, J. A. & ACKERMAN, S. L. 2003. Oxidative stress, cell cycle, and neurodegeneration. J Clin 
Invest, 111, 785-93. 
KLOTZ, L.-O., SÁNCHEZ-RAMOS, C., PRIETO-ARROYO, I., URBÁNEK, P., STEINBRENNER, H. 
& MONSALVE, M. 2015. Redox regulation of FoxO transcription factors. Redox biology, 6, 
51-72. 
KOBAYASHI, Y., FURUKAWA-HIBI, Y., CHEN, C., HORIO, Y., ISOBE, K., IKEDA, K. & 
MOTOYAMA, N. 2005. SIRT1 is critical regulator of FOXO-mediated transcription in 
response to oxidative stress. Int J Mol Med, 16, 237-43. 
KOINI, M., DUERING, M., GESIERICH, B. G., ROMBOUTS, S. A. R. B., ROPELE, S., WAGNER, 
95 
 
F., ENZINGER, C. & SCHMIDT, R. 2018. Grey-matter network disintegration as predictor of 
cognitive and motor function with aging. Brain Structure and Function, 223, 2475-2487. 
KOVALEVICH, J. & LANGFORD, D. 2013. Considerations for the use of SH-SY5Y neuroblastoma 
cells in neurobiology. Methods in molecular biology (Clifton, N.J.), 1078, 9-21. 
KURITA, M., HOLLOWAY, T., GARCÍA-BEA, A., KOZLENKOV, A., FRIEDMAN, A. K., MORENO, 
J. L., HESHMATI, M., GOLDEN, S. A., KENNEDY, P. J., TAKAHASHI, N., DIETZ, D. M., 
MOCCI, G., GABILONDO, A. M., HANKS, J., UMALI, A., CALLADO, L. F., GALLITANO, 
A. L., NEVE, R. L., SHEN, L., BUXBAUM, J. D., HAN, M.-H., NESTLER, E. J., MEANA, J. 
J., RUSSO, S. J. & GONZÁLEZ-MAESO, J. 2012. HDAC2 regulates atypical antipsychotic 
responses through the modulation of mGlu2 promoter activity. Nature neuroscience, 15, 1245-
1254. 
KUSUMI, I., TAKAHASHI, Y., SUZUKI, K., KAMEDA, K. & KOYAMA, T. 2000. Differential effects 
of subchronic treatments with atypical antipsychotic drugs on dopamine D2 and serotonin 5-
HT2A receptors in the rat brain. J Neural Transm (Vienna), 107, 295-302. 
LALLY, J. & MACCABE, J. H. 2015. Antipsychotic medication in schizophrenia: a review. Br Med Bull, 
114, 169-79. 
LAROUCHE, A., BERUBE, P., SARRET, P. & GRIGNON, S. 2008. Subacute H2O2, but not poly(IC), 
upregulates dopamine D2 receptors in retinoic acid differentiated SH-SY5Y neuroblastoma. 
Synapse, 62, 70-3. 
LAWLOR, P. G. 2002. The panorama of opioid-related cognitive dysfunction in patients with cancer: a 
96 
 
critical literature appraisal. Cancer, 94, 1836-53. 
LECHNER, T., CARROZZA, M. J., YU, Y., GRANT, P. A., EBERHARTER, A., VANNIER, D., 
BROSCH, G., STILLMAN, D. J., SHORE, D. & WORKMAN, J. L. 2000. Sds3 (suppressor of 
defective silencing 3) is an integral component of the yeast Sin3[middle dot]Rpd3 histone 
deacetylase complex and is required for histone deacetylase activity. J Biol Chem, 275, 40961-
6. 
LEE, C., KIM, B. G., KIM, J. H., CHUN, J., IM, J. P. & KIM, J. S. 2017. Sodium butyrate inhibits the 
NF-kappa B signaling pathway and histone deacetylation, and attenuates experimental colitis in 
an IL-10 independent manner. International Immunopharmacology, 51, 47-56. 
LEE, L., KANG, S. A., LEE, H. O., LEE, B. H., PARK, J. S., KIM, J. H., JUNG, I. K., PARK, Y. J. & 
LEE, J. E. 2001. Relationships between dietary intake and cognitive function level in Korean 
elderly people. Public Health, 115, 133-8. 
LEI, E., VACY, K. & BOON, W. C. 2016. Fatty acids and their therapeutic potential in neurological 
disorders. Neurochemistry International, 95, 75-84. 
LEUCHT, S., CORVES, C., ARBTER, D., ENGEL, R. R., LI, C. & DAVIS, J. M. 2009. Second-
generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. The 
Lancet, 373, 31-41. 
LEWIS, D. A. & LIEBERMAN, J. A. 2000. Catching up on schizophrenia: natural history and 
neurobiology. Neuron, 28, 325-34. 
97 
 
LI, H., SUN, J., WANG, F., DING, G., CHEN, W., FANG, R., YAO, Y., PANG, M., LU, Z.-Q. & LIU, J. 
2016. Sodium butyrate exerts neuroprotective effects by restoring the blood-brain barrier in 
traumatic brain injury mice. Brain Research, 1642, 70-78. 
LI, X. H., CHEN, C., TU, Y., SUN, H.-T., ZHAO, M.-L., CHENG, S.-X., QU, Y. & ZHANG, S. 2013. 
Sirt1 Promotes Axonogenesis by Deacetylation of Akt and Inactivation of GSK3. Molecular 
Neurobiology, 48, 490-499. 
LI, Y. & ZHANG, Z. 2015. Gastrodin improves cognitive dysfunction and decreases oxidative stress in 
vascular dementia rats induced by chronic ischemia. International journal of clinical and 
experimental pathology, 8, 14099-14109. 
LIDOW, M. S., SONG, Z. M., CASTNER, S. A., ALLEN, P. B., GREENGARD, P. & GOLDMAN-
RAKIC, P. S. 2001. Antipsychotic treatment induces alterations in dendrite- and spine-
associated proteins in dopamine-rich areas of the primate cerebral cortex. Biol Psychiatry, 49, 
1-12. 
LIU, C. M., WANG, R. Y., SAIJILAFU, JIAO, Z. X., ZHANG, B. Y. & ZHOU, F. Q. 2013. MicroRNA-
138 and SIRT1 form a mutual negative feedback loop to regulate mammalian axon regeneration. 
Genes & development, 27, 1473-1483. 
LIU, D., TANG, H., LI, X.-Y., DENG, M.-F., WEI, N., WANG, X., ZHOU, Y.-F., WANG, D.-Q., FU, P., 
WANG, J.-Z., HÉBERT, S. S., CHEN, J.-G., LU, Y. & ZHU, L.-Q. 2017. Targeting the 
HDAC2/HNF-4A/miR-101b/AMPK Pathway Rescues Tauopathy and Dendritic Abnormalities 
in Alzheimer’s Disease. Molecular Therapy, 25, 752-764. 
98 
 
LIU, R., LIU, I. Y., BI, X., THOMPSON, R. F., DOCTROW, S. R., MALFROY, B. & BAUDRY, M. 
2003. Reversal of age-related learning deficits and brain oxidative stress in mice with 
superoxide dismutase/catalase mimetics. Proc Natl Acad Sci U S A, 100, 8526-31. 
LODISH, H., DARNELL, J. E., BERK, A., KAISER, C. A., KRIEGER, M., SCOTT, M. P., 
BRETSCHER, A., PLOEGH, H. & MATSUDAIRA, P. 2008. Molecular cell biology, 
Macmillan. 
LOSCHEN, G., AZZI, A., RICHTER, C. & FLOHÉ, L. 1974. Superoxide radicals as precursors of 
mitochondrial hydrogen peroxide. FEBS Lett, 42, 68-72. 
LUFT, B. & TAYLOR, D. 2006. A review of atypical antipsychotic drugs versus conventional medication 
in schizophrenia. Expert Opin Pharmacother, 7, 1739-48. 
MAHADIK, S. P. & MUKHERJEE, S. 1996. Free radical pathology and antioxidant defense in 
schizophrenia: a review. Schizophr Res, 19, 1-17. 
MATSUZAKI, M., ELLIS-DAVIES, G. C., NEMOTO, T., MIYASHITA, Y., IINO, M. & KASAI, H. 
2001. Dendritic spine geometry is critical for AMPA receptor expression in hippocampal CA1 
pyramidal neurons. Nat Neurosci, 4, 1086-92. 
MATTSON, M. P. & CAMANDOLA, S. 2001. NF-kappaB in neuronal plasticity and neurodegenerative 
disorders. The Journal of clinical investigation, 107, 247-254. 
MEISSNER, A., VISANJI, N. P., MOMEN, M. A., FENG, R., FRANCIS, B. M., BOLZ, S. S. & 
HAZRATI, L. N. 2015. Tumor Necrosis Factor‐α Underlies Loss of Cortical Dendritic Spine 
99 
 
Density in a Mouse Model of Congestive Heart Failure. Journal of the American Heart 
Association, 4, e001920. 
MENDELL, A. L., CREIGHTON, C. E., KALISCH, B. E. & MACLUSKY, N. J. 2016. 5α-Androstane-
3α,17β-Diol Inhibits Neurotoxicity in SH-SY5Y Human Neuroblastoma Cells and Mouse 
Primary Cortical Neurons. Endocrinology, 157, 4570-4578. 
MICHÁN, S., LI, Y., CHOU, M. M., PARRELLA, E., GE, H., LONG, J. M., ALLARD, J. S., LEWIS, 
K., MILLER, M., XU, W., MERVIS, R. F., CHEN, J., GUERIN, K. I., SMITH, L. E., 
MCBURNEY, M. W., SINCLAIR, D. A., BAUDRY, M., DE CABO, R. & LONGO, V. D. 2010. 
SIRT1 is essential for normal cognitive function and synaptic plasticity. J Neurosci, 30, 9695-
707. 
MIN, S. W., CHO, S. H., ZHOU, Y., SCHROEDER, S., HAROUTUNIAN, V., SEELEY, W. W., HUANG, 
E. J., SHEN, Y., MASLIAH, E., MUKHERJEE, C., MEYERS, D., COLE, P. A., OTT, M. & 
GAN, L. 2010. Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron, 
67, 953-966. 
MIYAMOTO, S., MIYAKE, N., JARSKOG, L. F., FLEISCHHACKER, W. W. & LIEBERMAN, J. A. 
2012. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and 
clinical effects of current and future therapeutic agents. Mol Psychiatry, 17, 1206-27. 
MORIARTY, O., MCGUIRE, B. E. & FINN, D. P. 2011. The effect of pain on cognitive function: A 
review of clinical and preclinical research. Progress in Neurobiology, 93, 385-404. 
MORRIS, M. J., MAHGOUB, M., NA, E. S., PRANAV, H. & MONTEGGIA, L. M. 2013. Loss of 
100 
 
histone deacetylase 2 improves working memory and accelerates extinction learning. J Neurosci, 
33, 6401-11. 
MULLER, F. 2000. The nature and mechanism of superoxide production by the electron transport chain: 
Its relevance to aging. J Am Aging Assoc, 23, 227-53. 
MUNRO, D. & TREBERG, J. R. 2017. A radical shift in perspective: mitochondria as regulators of 
reactive oxygen species. J Exp Biol, 220, 1170-1180. 
NASRIN, N., KAUSHIK, V. K., FORTIER, E., WALL, D., PEARSON, K. J., DE CABO, R. & 
BORDONE, L. 2009. JNK1 Phosphorylates SIRT1 and Promotes Its Enzymatic Activity. PLOS 
ONE, 4, e8414. 
NATHAN, C. & CUNNINGHAM-BUSSEL, A. 2013. Beyond oxidative stress: an immunologist's guide 
to reactive oxygen species. Nature Reviews Immunology, 13, 349-361. 
NIELSEN, R. E., LEVANDER, S., KJAERSDAM TELLEUS, G., JENSEN, S. O., OSTERGAARD 
CHRISTENSEN, T. & LEUCHT, S. 2015. Second-generation antipsychotic effect on cognition 
in patients with schizophrenia--a meta-analysis of randomized clinical trials. Acta Psychiatr 
Scand, 131, 185-96. 
NIU, J., CAO, Y. & JI, Y. 2020. Resveratrol, a SIRT1 Activator, Ameliorates MK-801-Induced Cognitive 
and Motor Impairments in a Neonatal Rat Model of Schizophrenia. Frontiers in Psychiatry, 11. 
NOGUEIRAS, R., HABEGGER, K. M., CHAUDHARY, N., FINAN, B., BANKS, A. S., DIETRICH, 
M. O., HORVATH, T. L., SINCLAIR, D. A., PFLUGER, P. T. & TSCHÖP, M. H. 2012. Sirtuin 
101 
 
1 and Sirtuin 3: Physiological Modulators of Metabolism. Physiological Reviews, 92, 1479-
1514. 
NOLAN, G. P. 2007. What's wrong with drug screening today. Nat Chem Biol, 3, 187-91. 
OLDENDORF, W. H. 1973. Carrier-mediated blood-brain barrier transport of short-chain 
monocarboxylic organic acids. Am J Physiol, 224, 1450-3. 
OWEN, M. J., CRADDOCK, N. & O'DONOVAN, M. C. 2005. Schizophrenia: genes at last? Trends in 
Genetics, 21, 518-525. 
PANT, K., SARAYA, A. & VENUGOPAL, S. K. 2017a. Oxidative stress plays a key role in butyrate-
mediated autophagy via Akt/mTOR pathway in hepatoma cells. Chemico-Biological 
Interactions, 273, 99-106. 
PANT, K., YADAV, A. K., GUPTA, P., ISLAM, R., SARAYA, A. & VENUGOPAL, S. K. 2017b. 
Butyrate induces ROS-mediated apoptosis by modulating miR-22/SIRT-1 pathway in hepatic 
cancer cells. Redox Biology, 12, 340-349. 
PARDO, P. S., MOHAMED, J. S., LOPEZ, M. A. & BORIEK, A. M. 2011. Induction of Sirt1 by 
mechanical stretch of skeletal muscle through the early response factor EGR1 triggers an 
antioxidative response. The Journal of biological chemistry, 286, 2559-2566. 
PARK, S.-Y. & KIM, J.-S. 2020. A short guide to histone deacetylases including recent progress on class 
II enzymes. Experimental & Molecular Medicine, 52, 204-212. 
PARRINI, M., GHEZZI, D., DEIDDA, G., MEDRIHAN, L., CASTROFLORIO, E., ALBERTI, M., 
102 
 
BALDELLI, P., CANCEDDA, L. & CONTESTABILE, A. 2017. Aerobic exercise and a BDNF-
mimetic therapy rescue learning and memory in a mouse model of Down syndrome. Scientific 
reports, 7, 16825-16825. 
PESERICO, A. & SIMONE, C. 2010. Physical and functional HAT/HDAC interplay regulates protein 
acetylation balance. BioMed Research International, 2011. 
POLYDORO, M., SCHRÖDER, N., LIMA, M. N. M., CALDANA, F., LARANJA, D. C., BROMBERG, 
E., ROESLER, R., QUEVEDO, J., MOREIRA, J. C. F. & DAL-PIZZOL, F. 2004. Haloperidol- 
and clozapine-induced oxidative stress in the rat brain. Pharmacology Biochemistry and 
Behavior, 78, 751-756. 
PRABAKARAN, S., SWATTON, J. E., RYAN, M. M., HUFFAKER, S. J., HUANG, J.-J., GRIFFIN, J. 
L., WAYLAND, M., FREEMAN, T., DUDBRIDGE, F., LILLEY, K. S., KARP, N. A., HESTER, 
S., TKACHEV, D., MIMMACK, M. L., YOLKEN, R. H., WEBSTER, M. J., TORREY, E. F. 
& BAHN, S. 2004. Mitochondrial dysfunction in schizophrenia: evidence for compromised 
brain metabolism and oxidative stress. Molecular Psychiatry, 9, 684-697. 
REDDY, D. S., WU, X., GOLUB, V. M., DASHWOOD, W. M. & DASHWOOD, R. H. 2018. Measuring 
Histone Deacetylase Inhibition in the Brain. Current protocols in pharmacology, 81, e41-e41. 
RINK, C. & KHANNA, S. 2011. Significance of brain tissue oxygenation and the arachidonic acid 
cascade in stroke. Antioxidants & redox signaling, 14, 1889-1903. 
RIPKE, S., NEALE, B. M., CORVIN, A., WALTERS, J. T. R., FARH, K.-H., HOLMANS, P. A., LEE, 
P., BULIK-SULLIVAN, B., COLLIER, D. A., HUANG, H., PERS, T. H., AGARTZ, I., 
103 
 
AGERBO, E., ALBUS, M., ALEXANDER, M., AMIN, F., BACANU, S. A., BEGEMANN, M., 
BELLIVEAU JR, R. A., BENE, J., BERGEN, S. E., BEVILACQUA, E., BIGDELI, T. B., 
BLACK, D. W., BRUGGEMAN, R., BUCCOLA, N. G., BUCKNER, R. L., BYERLEY, W., 
CAHN, W., CAI, G., CAMPION, D., CANTOR, R. M., CARR, V. J., CARRERA, N., CATTS, 
S. V., CHAMBERT, K. D., CHAN, R. C. K., CHEN, R. Y. L., CHEN, E. Y. H., CHENG, W., 
CHEUNG, E. F. C., ANN CHONG, S., ROBERT CLONINGER, C., COHEN, D., COHEN, N., 
CORMICAN, P., CRADDOCK, N., CROWLEY, J. J., CURTIS, D., DAVIDSON, M., DAVIS, 
K. L., DEGENHARDT, F., DEL FAVERO, J., DEMONTIS, D., DIKEOS, D., DINAN, T., 
DJUROVIC, S., DONOHOE, G., DRAPEAU, E., DUAN, J., DUDBRIDGE, F., DURMISHI, 
N., EICHHAMMER, P., ERIKSSON, J., ESCOTT-PRICE, V., ESSIOUX, L., FANOUS, A. H., 
FARRELL, M. S., FRANK, J., FRANKE, L., FREEDMAN, R., FREIMER, N. B., FRIEDL, 
M., FRIEDMAN, J. I., FROMER, M., GENOVESE, G., GEORGIEVA, L., GIEGLING, I., 
GIUSTI-RODRÍGUEZ, P., GODARD, S., GOLDSTEIN, J. I., GOLIMBET, V., GOPAL, S., 
GRATTEN, J., DE HAAN, L., HAMMER, C., HAMSHERE, M. L., HANSEN, M., HANSEN, 
T., HAROUTUNIAN, V., HARTMANN, A. M., HENSKENS, F. A., HERMS, S., 
HIRSCHHORN, J. N., HOFFMANN, P., HOFMAN, A., HOLLEGAARD, M. V., 
HOUGAARD, D. M., IKEDA, M., JOA, I., et al. 2014. Biological insights from 108 
schizophrenia-associated genetic loci. Nature, 511, 421-427. 
ROCHEFORT, N. L. & KONNERTH, A. 2012. Dendritic spines: from structure to in vivo function. 
EMBO Rep, 13, 699-708. 
ROSE, S., BENNURI, S. C., DAVIS, J. E., WYNNE, R., SLATTERY, J. C., TIPPETT, M., DELHEY, 
104 
 
L., MELNYK, S., KAHLER, S. G., MACFABE, D. F. & FRYE, R. E. 2018. Butyrate enhances 
mitochondrial function during oxidative stress in cell lines from boys with autism. Translational 
Psychiatry, 8, 42. 
ROSENGARTEN, H. & QUARTERMAIN, D. 2002. The effect of chronic treatment with typical and 
atypical antipsychotics on working memory and jaw movements in three- and eighteen-month-
old rats. Prog Neuropsychopharmacol Biol Psychiatry, 26, 1047-54. 
ROTH, B. L., CRAIGO, S. C., CHOUDHARY, M. S., ULUER, A., MONSMA, F. J., JR., SHEN, Y., 
MELTZER, H. Y. & SIBLEY, D. R. 1994. Binding of typical and atypical antipsychotic agents 
to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther, 268, 
1403-10. 
SALMINEN, A., HUUSKONEN, J., OJALA, J., KAUPPINEN, A., KAARNIRANTA, K. & 
SUURONEN, T. 2008a. Activation of innate immunity system during aging: NF-kB signaling 
is the molecular culprit of inflamm-aging. Ageing Research Reviews, 7, 83-105. 
SALMINEN, A., KAARNIRANTA, K. & KAUPPINEN, A. 2013. Crosstalk between Oxidative Stress 
and SIRT1: Impact on the Aging Process. International journal of molecular sciences, 14, 3834-
3859. 
SALMINEN, A., KAUPPINEN, A., SUURONEN, T. & KAARNIRANTA, K. 2008b. SIRT1 longevity 
factor suppresses NF‐κB‐driven immune responses: regulation of aging via NF‐κB acetylation? 
Bioessays, 30, 939-942. 
SARTOR, G. C., MALVEZZI, A. M., KUMAR, A., ANDRADE, N. S., WIEDNER, H. J., VILCA, S. J., 
105 
 
JANCZURA, K. J., BAGHERI, A., AL-ALI, H., POWELL, S. K., BROWN, P. T., VOLMAR, 
C. H., FOSTER, T. C., ZEIER, Z. & WAHLESTEDT, C. 2019. Enhancement of BDNF 
Expression and Memory by HDAC Inhibition Requires BET Bromodomain Reader Proteins. 
The Journal of neuroscience : the official journal of the Society for Neuroscience, 39, 612-626. 
SCHRECK, R., ALBERMANN, K. & BAEUERLE, P. A. 1992. Nuclear factor kB: an oxidative stress-
responsive transcription factor of eukaryotic cells (a review). Free radical research 
communications, 17, 221-237. 
SCHRÖDER, N., DE LIMA, M. N. M., QUEVEDO, J., DAL PIZZOL, F. & ROESLER, R. 2005. 
Impairing effects of chronic haloperidol and clozapine treatment on recognition memory: 
possible relation to oxidative stress. Schizophrenia Research, 73, 377-378. 
SCHROEDER, F. A., LIN, C. L., CRUSIO, W. E. & AKBARIAN, S. 2007. Antidepressant-like effects 
of the histone deacetylase inhibitor, sodium butyrate, in the mouse. Biol Psychiatry, 62, 55-64. 
SEGAIN, J., DE LA BLÉTIERE, D. R., BOURREILLE, A., LERAY, V., GERVOIS, N., ROSALES, C., 
FERRIER, L., BONNET, C., BLOTTIERE, H. & GALMICHE, J. 2000. Butyrate inhibits 
inflammatory responses through NFκB inhibition: implications for Crohn's disease. Gut, 47, 
397-403. 
SEGRÉ, C. V. & CHIOCCA, S. 2011. Regulating the regulators: the post-translational code of class I 
HDAC1 and HDAC2. Journal of biomedicine & biotechnology, 2011, 690848-690848. 
SERASANAMBATI, M. & CHILAKAPATI, S. R. 2016. Function of nuclear factor kappa B (NF-kB) in 
human diseases-a review. South Indian Journal of Biological Sciences, 2, 368-387. 
106 
 
SHOLL, D. A. 1953. Dendritic organization in the neurons of the visual and motor cortices of the cat. 
Journal of anatomy, 87, 387. 
SHUKLA, S., SHARIAT-MADAR, Z., WALKER, L. A. & TEKWANI, B. L. 2016. Mechanism for 
neurotropic action of vorinostat, a pan histone deacetylase inhibitor. Molecular and Cellular 
Neuroscience, 77, 11-20. 
SIEBZEHNRÜBL, F. A., RABER, K. A., URBACH, Y. K., SCHULZE-KREBS, A., CANNEVA, F., 
MOCERI, S., HABERMEYER, J., ACHOUI, D., GUPTA, B., STEINDLER, D. A., STEPHAN, 
M., NGUYEN, H. P., BONIN, M., RIESS, O., BAUER, A., AIGNER, L., COUILLARD-
DESPRES, S., PAUCAR, M. A., SVENNINGSSON, P., OSMAND, A., ANDREEW, A., 
ZABEL, C., WEISS, A., KUHN, R., MOUSSAOUI, S., BLOCKX, I., VAN DER LINDEN, A., 
CHEONG, R. Y., ROYBON, L., PETERSÉN, Å. & VON HÖRSTEN, S. 2018. Early postnatal 
behavioral, cellular, and molecular changes in models of Huntington disease are reversible by 
HDAC inhibition. Proc Natl Acad Sci U S A, 115, E8765-e8774. 
SIES, H. 1997. Oxidative stress: oxidants and antioxidants. Experimental Physiology: Translation and 
Integration, 82, 291-295. 
SILVA, L. G., FERGUSON, B. S., AVILA, A. S. & FACIOLA, A. P. 2018. Sodium propionate and 
sodium butyrate effects on histone deacetylase (HDAC) activity, histone acetylation, and 
inflammatory gene expression in bovine mammary epithelial cells. J Anim Sci, 96, 5244-5252. 
SKARSFELDT, T. 1996. Differential effect of antipsychotics on place navigation of rats in the Morris 
water maze. A comparative study between novel and reference antipsychotics. 
107 
 
Psychopharmacology (Berl), 124, 126-33. 
SOLIMAN, M. L. & ROSENBERGER, T. A. 2011. Acetate supplementation increases brain histone 
acetylation and inhibits histone deacetylase activity and expression. Mol Cell Biochem, 352, 
173-80. 
SONG, X. Q., LV, L. X., LI, W. Q., HAO, Y. H. & ZHAO, J. P. 2009. The interaction of nuclear factor-
kappa B and cytokines is associated with schizophrenia. Biol Psychiatry, 65, 481-8. 
STARK, A. & SCOTT, J. 2012. A review of the use of clozapine levels to guide treatment and determine 
cause of death. Aust N Z J Psychiatry, 46, 816-25. 
STRAHL, B. D. & ALLIS, C. D. 2000. The language of covalent histone modifications. Nature, 403, 41. 
STRICKLAND, I. & GHOSH, S. 2006. Use of cell permeable NBD peptides for suppression of 
inflammation. Ann Rheum Dis, 65 Suppl 3, iii75-82. 
SUGINO, T., MARUYAMA, M., TANNO, M., KUNO, A., HOUKIN, K. & HORIO, Y. 2010. Protein 
deacetylase SIRT1 in the cytoplasm promotes nerve growth factor-induced neurite outgrowth 
in PC12 cells. FEBS Lett, 584, 2821-6. 
SUZUKAWA, K., MIURA, K., MITSUSHITA, J., RESAU, J., HIROSE, K., CRYSTAL, R. & KAMATA, 
T. 2000. Nerve growth factor-induced neuronal differentiation requires generation of Rac1-
regulated reactive oxygen species. J Biol Chem, 275, 13175-8. 
SUZUKI-MIZUSHIMA, Y., GOHDA, E., OKAMURA, T., KANASAKI, K. & YAMAMOTO, I. 2002. 
Enhancement of NGF- and cholera toxin-induced neurite outgrowth by butyrate in PC12 cells. 
108 
 
Brain Research, 951, 209-217. 
TAKADA, Y., MUKHOPADHYAY, A., KUNDU, G. C., MAHABELESHWAR, G. H., SINGH, S. & 
AGGARWAL, B. B. 2003. Hydrogen peroxide activates NF-kappa B through tyrosine 
phosphorylation of I kappa B alpha and serine phosphorylation of p65: evidence for the 
involvement of I kappa B alpha kinase and Syk protein-tyrosine kinase. J Biol Chem, 278, 
24233-41. 
TAKUMA, K., HARA, Y., KATAOKA, S., KAWANAI, T., MAEDA, Y., WATANABE, R., TAKANO, 
E., HAYATA-TAKANO, A., HASHIMOTO, H., AGO, Y. & MATSUDA, T. 2014. Chronic 
treatment with valproic acid or sodium butyrate attenuates novel object recognition deficits and 
hippocampal dendritic spine loss in a mouse model of autism. Pharmacol Biochem Behav, 126, 
43-9. 
TAOUFIK, E., KOUROUPI, G., ZYGOGIANNI, O. & MATSAS, R. 2018. Synaptic dysfunction in 
neurodegenerative and neurodevelopmental diseases: an overview of induced pluripotent stem-
cell-based disease models. Open biology, 8, 180138. 
THOMAS, C. S. & LEWIS, S. 1998. Which atypical antipsychotic? British Journal of Psychiatry, 172, 
106-109. 
TIMMERMANN, S., LEHRMANN, H., POLESSKAYA, A. & HAREL-BELLAN, A. 2001. Histone 
acetylation and disease. Cellular and Molecular Life Sciences CMLS, 58, 728-736. 
TODOROVIĆ, N., TOMANOVIĆ, N., GASS, P. & FILIPOVIĆ, D. 2016. Olanzapine modulation of 
hepatic oxidative stress and inflammation in socially isolated rats. Eur J Pharm Sci, 81, 94-102. 
109 
 
TYLER, W. J. & POZZO-MILLER, L. 2003. Miniature synaptic transmission and BDNF modulate 
dendritic spine growth and form in rat CA1 neurones. The Journal of Physiology, 553, 497-509. 
TYLER, W. J. & POZZO-MILLER, L. D. 2001. BDNF Enhances Quantal Neurotransmitter Release and 
Increases the Number of Docked Vesicles at the Active Zones of Hippocampal Excitatory 
Synapses. The Journal of Neuroscience, 21, 4249-4258. 
UITTENBOGAARD, M., BRANTNER, C. A. & CHIARAMELLO, A. 2018. Epigenetic modifiers 
promote mitochondrial biogenesis and oxidative metabolism leading to enhanced differentiation 
of neuroprogenitor cells. Cell Death & Disease, 9, 360. 
UKAI, W., OZAWA, H., TATENO, M., HASHIMOTO, E. & SAITO, T. 2004. Neurotoxic potential of 
haloperidol in comparison with risperidone: implication of Akt-mediated signal changes by 
haloperidol. J Neural Transm (Vienna), 111, 667-81. 
VALVASSORI, S. S., DAL-PONT, G. C., STECKERT, A. V., VARELA, R. B., LOPES-BORGES, J., 
MARIOT, E., RESENDE, W. R., ARENT, C. O., CARVALHO, A. F. & QUEVEDO, J. 2016. 
Sodium butyrate has an antimanic effect and protects the brain against oxidative stress in an 
animal model of mania induced by ouabain. Psychiatry Research, 235, 154-159. 
VAN DEN BERG, R., HAENEN, G., VAN DEN BERG, H. & BAST, A. 2001. Transcription factor NF-
κB as a potential biomarker for oxidative stress. British Journal of Nutrition, 86, S121-S127. 
VAN HAREN, N. E. M., SCHNACK, H. G., CAHN, W., VAN DEN HEUVEL, M. P., LEPAGE, C., 
COLLINS, L., EVANS, A. C., POL, H. E. H. & KAHN, R. S. 2011. Changes in Cortical 




VERNON, A. C., CRUM, W. R., LERCH, J. P., CHEGE, W., NATESAN, S., MODO, M., COOPER, J. 
D., WILLIAMS, S. C. R. & KAPUR, S. 2014. Reduced cortical volume and elevated astrocyte 
density in rats chronically treated with antipsychotic drugs-linking magnetic resonance imaging 
findings to cellular pathology. Biological Psychiatry, 75, 982-990. 
VERNON, A. C., NATESAN, S., MODO, M. & KAPUR, S. 2011. Effect of chronic antipsychotic 
treatment on brain structure: a serial magnetic resonance imaging study with ex vivo and 
postmortem confirmation. Biol Psychiatry, 69, 936-44. 
VITA, A., DE PERI, L., DESTE, G., BARLATI, S. & SACCHETTI, E. 2015. The Effect of Antipsychotic 
Treatment on Cortical Gray Matter Changes in Schizophrenia: A Meta-analysis and Meta-
regression of Longitudinal Magnetic Resonance Imaging Studies. Biol Psychiatry, 403-12. 
VOGELAUER, M., KRALL, A. S., MCBRIAN, M. A., LI, J. Y. & KURDISTANI, S. K. 2012. 
Stimulation of histone deacetylase activity by metabolites of intermediary metabolism. J Biol 
Chem, 287, 32006-16. 
VUCICEVIC, L., MISIRKIC-MARJANOVIC, M., PAUNOVIC, V., KRAVIC-STEVOVIC, T., 
MARTINOVIC, T., CIRIC, D., MARIC, N., PETRICEVIC, S., HARHAJI-TRAJKOVIC, L., 
BUMBASIREVIC, V. & TRAJKOVIC, V. 2014. Autophagy inhibition uncovers the neurotoxic 
action of the antipsychotic drug olanzapine. Autophagy, 10, 2362-2378. 
WINCKEL, K. & SISKIND, D. 2017. Clozapine in primary care. Australian prescriber, 40, 231-236. 
111 
 
WISHART, D. S., FEUNANG, Y. D., MARCU, A., GUO, A. C., LIANG, K., VÁZQUEZ-FRESNO, R., 
SAJED, T., JOHNSON, D., LI, C., KARU, N., SAYEEDA, Z., LO, E., ASSEMPOUR, N., 
BERJANSKII, M., SINGHAL, S., ARNDT, D., LIANG, Y., BADRAN, H., GRANT, J., 
SERRA-CAYUELA, A., LIU, Y., MANDAL, R., NEVEU, V., PON, A., KNOX, C., WILSON, 
M., MANACH, C. & SCALBERT, A. 2018. HMDB 4.0: the human metabolome database for 
2018. Nucleic Acids Res, 46, D608-d617. 
WOOD, J. G., ROGINA, B., LAVU, S., HOWITZ, K., HELFAND, S. L., TATAR, M. & SINCLAIR, D. 
2004. Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature, 430, 
686-689. 
WU, A., YING, Z. & GOMEZ‐PINILLA, F. 2004. The interplay between oxidative stress and brain‐
derived neurotrophic factor modulates the outcome of a saturated fat diet on synaptic plasticity 
and cognition. European Journal of Neuroscience, 19, 1699-1707. 
XING, X., JIANG, Z., TANG, X., WANG, P., LI, Y., SUN, Y., LE, G. & ZOU, S. 2016. Sodium butyrate 
protects against oxidative stress in HepG2 cells through modulating Nrf2 pathway and 
mitochondrial function. Journal of Physiology and Biochemistry, 73, 405-414. 
XU, K., DAI, X.-L., HUANG, H.-C. & JIANG, Z.-F. 2011. Targeting HDACs: a promising therapy for 
Alzheimer's disease. Oxidative medicine and cellular longevity, 2011. 
YAMAKAWA, H., CHENG, J., PENNEY, J., GAO, F., RUEDA, R., WANG, J., YAMAKAWA, S., 
KRITSKIY, O., GJONESKA, E. & TSAI, L. H. 2017. The Transcription Factor Sp3 Cooperates 
with HDAC2 to Regulate Synaptic Function and Plasticity in Neurons. Cell Rep, 20, 1319-1334. 
112 
 
YAMAKUCHI, M., FERLITO, M. & LOWENSTEIN, C. J. 2008. miR-34a repression of SIRT1 
regulates apoptosis. Proceedings of the National Academy of Sciences of the United States of 
America, 105, 13421-13426. 
YEUNG, F., HOBERG, J. E., RAMSEY, C. S., KELLER, M. D., JONES, D. R., FRYE, R. A. & MAYO, 
M. W. 2004. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 
deacetylase. The EMBO journal, 23, 2369-2380. 
YOO, D. Y., KIM, W., NAM, S. M., KIM, D. W., CHUNG, J. Y., CHOI, S. Y., YOON, Y. S., WON, M. 
H. & HWANG, I. K. 2011. Synergistic effects of sodium butyrate, a histone deacetylase inhibitor, 
on increase of neurogenesis induced by pyridoxine and increase of neural proliferation in the 
mouse dentate gyrus. Neurochem Res, 36, 1850-7. 
YUAN, T. F., GU, S., SHAN, C., MARCHADO, S. & ARIAS-CARRIÓN, O. 2015. Oxidative Stress 
and Adult Neurogenesis. Stem Cell Rev Rep, 11, 706-9. 
ZHANG, C., YI, S., CHEN, B., CUI, P., WANG, Y. & LI, Y. 2020. mTOR/NF-kappaB signaling pathway 
protects hippocampal neurons from injury induced by intermittent hypoxia in rats. Int J Neurosci, 
1-10. 
ZHANG, X. Y., CHEN, D. C., TAN, Y. L., TAN, S. P., WANG, Z. R., YANG, F. D., OKUSAGA, O. O., 
ZUNTA-SOARES, G. B. & SOARES, J. C. 2015. The interplay between BDNF and oxidative 
stress in chronic schizophrenia. Psychoneuroendocrinology, 51, 201-8. 
ZHANG, X. Y., CHEN, D. C., XIU, M. H., TANG, W., ZHANG, F., LIU, L., CHEN, Y., LIU, J., YAO, 
J. K., KOSTEN, T. A. & KOSTEN, T. R. 2012. Plasma total antioxidant status and cognitive 
113 
 
impairments in schizophrenia. Schizophr Res, 139, 66-72. 
ZHANG, Y., NG, H. H., ERDJUMENT-BROMAGE, H., TEMPST, P., BIRD, A. & REINBERG, D. 
1999. Analysis of the NuRD subunits reveals a histone deacetylase core complex and a 
connection with DNA methylation. Genes & development, 13, 1924-1935. 
ZIV, N. E. & SMITH, S. J. 1996. Evidence for a role of dendritic filopodia in synaptogenesis and spine 


















APPENDIX OF SUPPLEMENTARY METHODS 
 
Preparation of the homogeneous buffer 
0.5mM β-glycerophosphate (G-9422, Sigma Aldrich) 
1mM phenylmethyl-sulfonyl fluoride (PMSF, P7626, Sigma Aldrich) 
Protease inhibitor cocktail (100X, PIC, P-8340, Sigma Aldrich)  
Dissolved in NP-40 cell lysis buffer (FNN0021, Thermofisher) 
 
 
Preparation of the buffer used in the culture of primary cortical neuron  
 
Dissection solution (500ml): 
4g NaCl (S-7653, Sigma Aldrich) 
0.2g KCl (P-9333, Sigma Aldrich) 
12mg Na2HPO4 (S-7907, Sigma Aldrich) 
15mg KH2PO4 (P-5379, Sigma Aldrich) 
3g D-(+)-Glucose (G-8270, Sigma Aldrich) 
7.5g Sucrose (S-9378, Sigma Aldrich) 
Dissolved in 1M HEPES (H-7523, Sigma Aldrich), with pH=7.4 by using 1N 
NaOH (S-8045, Sigma Aldrich) 
 
Enzyme solution (100ml): 
16 mg L-Cysteine (C-5360, Sigma Aldrich) 
1000 units papain (P-4762, Sigma Aldrich) 
140μl 0.1N NaOH  
1ml 5mM 2-Amino-5-phosphonopentanoic acid (A5258, APV, Sigma Aldrich)  
Dissolved in 100ml dissection buffer 
